US20080090835A1 - Polymorphic forms of ziprasidone HCl and processes for their preparation - Google Patents
Polymorphic forms of ziprasidone HCl and processes for their preparation Download PDFInfo
- Publication number
- US20080090835A1 US20080090835A1 US11/999,337 US99933707A US2008090835A1 US 20080090835 A1 US20080090835 A1 US 20080090835A1 US 99933707 A US99933707 A US 99933707A US 2008090835 A1 US2008090835 A1 US 2008090835A1
- Authority
- US
- United States
- Prior art keywords
- ziprasidone
- hcl
- slurry
- ziprasidone hcl
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 title claims abstract description 300
- 229960000607 ziprasidone Drugs 0.000 title claims abstract description 155
- 238000000034 method Methods 0.000 title claims abstract description 29
- 230000008569 process Effects 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title abstract description 39
- 239000002002 slurry Substances 0.000 claims description 99
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 50
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 40
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 39
- 239000002904 solvent Substances 0.000 claims description 30
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 20
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 10
- 238000002441 X-ray diffraction Methods 0.000 claims description 8
- 238000001144 powder X-ray diffraction data Methods 0.000 claims description 8
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 90
- 239000002585 base Substances 0.000 description 74
- 239000007787 solid Substances 0.000 description 71
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 65
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 65
- 239000000203 mixture Substances 0.000 description 59
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 238000001035 drying Methods 0.000 description 18
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 18
- 229940093499 ethyl acetate Drugs 0.000 description 17
- 235000019439 ethyl acetate Nutrition 0.000 description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 238000002411 thermogravimetry Methods 0.000 description 15
- 239000000843 powder Substances 0.000 description 14
- 239000013078 crystal Substances 0.000 description 13
- 239000002552 dosage form Substances 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- ZCBZSCBNOOIHFP-UHFFFAOYSA-N ziprasidone hydrochloride hydrate Chemical compound [H+].O.[Cl-].C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 ZCBZSCBNOOIHFP-UHFFFAOYSA-N 0.000 description 11
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 10
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 9
- 229940116333 ethyl lactate Drugs 0.000 description 9
- 239000008187 granular material Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- -1 C12 hydrocarbon Chemical class 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 8
- 238000002329 infrared spectrum Methods 0.000 description 7
- 229940032007 methylethyl ketone Drugs 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229940113088 dimethylacetamide Drugs 0.000 description 5
- 238000007907 direct compression Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 150000004682 monohydrates Chemical class 0.000 description 5
- 239000008247 solid mixture Substances 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 150000004684 trihydrates Chemical class 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 229950005499 carbon tetrachloride Drugs 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229940014259 gelatin Drugs 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 229940003380 geodon Drugs 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 229960002900 methylcellulose Drugs 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 229940033134 talc Drugs 0.000 description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
- 241000220479 Acacia Species 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 238000000634 powder X-ray diffraction Methods 0.000 description 3
- 235000019814 powdered cellulose Nutrition 0.000 description 3
- 229920003124 powdered cellulose Polymers 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 235000010413 sodium alginate Nutrition 0.000 description 3
- 239000000661 sodium alginate Substances 0.000 description 3
- 229940005550 sodium alginate Drugs 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 235000019731 tricalcium phosphate Nutrition 0.000 description 3
- 229960003474 ziprasidone hydrochloride Drugs 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 239000004097 EU approved flavor enhancer Substances 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 229940022682 acetone Drugs 0.000 description 2
- 239000012615 aggregate Substances 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000005056 compaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 150000004683 dihydrates Chemical class 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical group CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000019264 food flavour enhancer Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008241 heterogeneous mixture Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 239000003176 neuroleptic agent Substances 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 230000010494 opalescence Effects 0.000 description 2
- 229940100691 oral capsule Drugs 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000206576 Chondrus Species 0.000 description 1
- 241000694440 Colpidium aqueous Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- YIKYNHJUKRTCJL-UHFFFAOYSA-N Ethyl maltol Chemical compound CCC=1OC=CC(=O)C=1O YIKYNHJUKRTCJL-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 229920003072 Plasdone™ povidone Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 229940092782 bentonite Drugs 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000010981 drying operation Methods 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 229940035423 ethyl ether Drugs 0.000 description 1
- 229940093503 ethyl maltol Drugs 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 230000008863 intramolecular interaction Effects 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 229940032159 propylene carbonate Drugs 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 229940057977 zinc stearate Drugs 0.000 description 1
- WLQZEFFFIUHSJB-UHFFFAOYSA-N ziprasidone mesylate trihydrate Chemical compound O.O.O.CS(O)(=O)=O.C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 WLQZEFFFIUHSJB-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Definitions
- the present invention relates to the solid state chemistry of ziprasidone HCl.
- Ziprasidone is an antipsychotic agent that is chemically unrelated to phenothiazine or butyrophenone antipsychotic agents. Ziprasidone has the following structure:
- ziprasidone base is disclosed in U.S. Pat. No. 4,831,031 (example 16). Preparation of ziprasidone base is also disclosed in U.S. Pat. No. 5,312,925. A process for preparation of ziprasidone HCl monohydrate having a mean particle size equal to or less than about 85 microns is also disclosed in U.S. Pat. No. 6,150,366 and EP 0 965 343 A2.
- Ziprasidone has been marketed under the name GEODON as an oral capsule and as an injectable drug.
- GEODON capsules contain the monohydrate hydrochloride salt of ziprasidone, and come in 20, 40, 60 and 80 mg dosage forms.
- GEODON for injection contains a lyophilized form of ziprasidone mesylate trihydrate, and contains 20 mg base equivalent of ziprasidone.
- the mesylate salts of ziprasidone, including monohydrate and trihydrate, are disclosed in U.S. Pat. Nos. 6,110,918 and 5,245,765.
- the present invention relates to the solid state physical properties of ziprasidone HCl.
- Solid state physical properties include, for example, the flowability of the milled solid. Flowability affects the ease with which the material is handled during processing into a pharmaceutical product. When particles of the powdered compound do not flow past each other easily, a formulation specialist must take that fact into account in developing a tablet or capsule formulation, which may necessitate the use of glidants such as colloidal silicon dioxide, talc, starch or tribasic calcium phosphate.
- Another important solid state property of a pharmaceutical compound is its rate of dissolution in aqueous fluid.
- the rate of dissolution of an active ingredient in a patient's stomach fluid can have therapeutic consequences since it imposes an upper limit on the rate at which an orally-administered active ingredient can reach the patient's bloodstream.
- the rate of dissolution is also a consideration in formulating syrups, elixirs and other liquid medicaments.
- the solid state form of a compound may also affect its behavior on compaction and its storage stability.
- a particular polymorphic form may give rise to distinct spectroscopic properties that may be detectable by powder X-Ray diffraction, solid state 13 C NMR spectrometry and infrared spectrometry.
- the polymorphic form may also give rise to thermal behavior different from that of the amorphous material or another polymorphic form. Thermal behavior is measured in the laboratory by such techniques as capillary melting point, thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) and can be used to distinguish some polymorphic forms from others.
- Ziprasidone HCl hemihydrate is disclosed in U.S. Pat. No. 4,831,031, Example 16 (column 13, line 13).
- a ziprasidone HCl monohydrate (herein designated Form M) is disclosed in U.S. Pat. No. 5,312,925 and EP 0 586 181 A1.
- Form M is characterized by XRD, IR and water content. It is reported that the water content of Form M ranges from 3.8 to 4.5% by weight.
- Ziprasidone HCl Form M is prepared from ziprasidone base anhydrous.
- the present invention provides a crystalline form of ziprasidone HCl (Form E), wherein the crystalline form is characterized by a powder XRD pattern with peaks at 7.4, 13.0, 20.7, 23.4, 25.9 ⁇ 0.2 degrees 2 theta.
- the present invention provides a process for preparing ziprasidone HCl Form E, comprising:
- the present invention provides a crystalline form of ziprasidone HCl, wherein the crystalline form is a trihydrate.
- the present invention provides a process for preparing ziprasidone HCl Form E in a mixture with a crystalline ziprasidone HCl having an X-Ray diffraction pattern having peaks at about 10.9, 17.4 and 19.1 ⁇ 0.2 degrees 2 theta, comprising:
- the present invention provides a crystalline form of ziprasidone HCl (Form F), wherein the crystalline form is characterized by a powder XRD pattern with peaks at 11.0, 18.1, 19.5, 21.9 ⁇ 0.2 degrees 2 theta.
- the present invention provides a process for preparing the ziprasidone HCl Form F, comprising:
- aqueous HCl with ziprasidone base in a solvent selected from the group consisting of methylethylketone, tetrahydrofuran and dimethylacetamide to obtain a slurry;
- the present invention provides a process for preparing the ziprasidone HCl form M, comprising:
- the present invention provides a process for preparing the ziprasidone HCl form M comprising:
- aqueous HCl with ziprasidone base at a temperature of at least about 40° C. in a solvent selected from the group consisting of ethanol, methanol, n-butanol, acetone, ethyl acetate, ethyl lactate, dimethyl-carbonate, optionally in a mixtures with water to obtain a slurry,
- the present invention provides a process for preparing the ziprasidone HCl form M comprising:
- the present invention provides a process for preparing the ziprasidone HCl form M substantially free of the crystalline ziprasidone HCl characterized by a powder XRD pattern with peaks at 10.9, 17.4, 19.1, 25.0, 26.0 ⁇ 0.2 degrees 2 theta comprising:
- the present invention provides for amorphous form of ziprasidone HCl.
- the present invention provides a process for preparing amorphous form comprising slurrying ziprasidone base with methyl ethyl ketone or mono-chloro benzene with gaseous hydrochloride.
- the present invention provides a crystalline form of ziprasidone HCl (Form G), wherein the crystalline form is characterized by a powder XRD pattern with peaks at 9.0, 20.6, 22.7, 25.0, 27.0 ⁇ 0.2 degrees 2 theta.
- the present invention provides a process for preparing ziprasidone HCl Form G comprising:
- the present invention provides a process for preparing a mixture of the ziprasidone HCl of Form F and ziprasidone HCl Form G comprising:
- the present invention provides a crystalline form of ziprasidone HCl (Form I), wherein the crystalline form has an XRD pattern with peaks at 15.8, 16.2, 18.9, 23.8, 27.0 ⁇ 0.2 degrees 2 theta,
- the present invention provides a crystalline form of ziprasidone HCl (Form J), wherein the crystalline form is characterized by a powder XRD pattern with peaks at 9.1, 19.1, 25.7, 26.3, 26.9 ⁇ 0.2 degrees 2 theta.
- the present invention provides a process for preparing ziprasidone HCl Form J comprising:
- the present invention provides a crystalline form of ziprasidone HCl, wherein the crystalline form has a water content of about 24% by LOD.
- the present invention provides a crystalline from of ziprasidone HCl (Form E1), wherein the crystalline form is characterized a powder XRD pattern with peaks at 7.5, 13.0, 21.2, 23.4 and 26.0 ⁇ 0.2 degrees 2 theta.
- the present invention provides a process for preparing ziprasidone HCl Form E1 comprising drying the ziprasidone HCl Form J.
- the present invention provides a crystalline form of ziprasidone, wherein the crystalline form has a water content of about 6% to about 8%.
- the present invention provides a pharmaceutical composition and method of treating a patient suffering from schizophrenia.
- FIG. 1 is an X-Ray powder diffractogram of amorphous ziprasidone HCl.
- FIG. 2 is a DSC thermogram of amorphous ziprasidone HCl.
- FIG. 3 is an IR spectrum of ziprasidone HCl amorphous.
- FIG. 4 is an X-Ray powder diffractogram of ziprasidone HCl form E.
- FIG. 5 is a DSC thermogram of ziprasidone HCl form E.
- FIG. 6 is an IR spectrum of ziprasidone HCl form E.
- FIG. 7 is an X-Ray powder diffractogram of ziprasidone HCl form F.
- FIG. 8 is a DSC thermogram of ziprasidone HCl form F.
- FIG. 9 is an IR spectrum of ziprasidone HCl form F.
- FIG. 10 is a DSC thermogram of ziprasidone HCl Form M.
- FIG. 11 is an IR spectrum of ziprasidone HCl Form M.
- FIG. 12 is an X-Ray powder diffractogram of ziprasidone Base.
- FIG. 13 is a DSC thermogram of ziprasidone Base.
- FIG. 14 is an IR spectrum of ziprasidone Base.
- FIG. 15 is an X-Ray powder diffractogram of ziprasidone HCl Form G.
- FIG. 16 is an X-Ray powder diffractogram of ziprasidone HCl Form I.
- FIG. 17 is an X-Ray powder diffractogram of ziprasidone HCl Form J.
- FIG. 18 is an FTIR spectrum of ziprasidone HCl Form J.
- FIG. 19 is an FTIR spectrum of ziprasidone HCl Form J.
- FIG. 20 is an FTIR spectrum of ziprasidone HCl Form J.
- FIG. 21 is an X-Ray powder diffractogram of ziprasidone HCl Form E1.
- FIG. 22 is an FTIR spectrum of ziprasidone HCl Form E1.
- FIG. 23 is an FTIR spectrum of ziprasidone HCl Form E1.
- FIG. 24 is an FTIR spectrum of ziprasidone HCl Form E1.
- slurry refers to a heterogeneous mixture.
- reduced pressure refers to a pressure below about 1 atm, more preferably below about 100 mmHg.
- the present invention provides for obtaining ziprasidone HCl Form M from ziprasidone base, or other forms of ziprasidone hydrochloride.
- Ziprasidone base such as form B, but not limited to this form, is combined with aqueous hydrochloric acid and slurried in solvents such as methanol, ethanol, n-butanol, ethyl acetate, ethyl lactate, acetone, dimethyl carbonate, optionally in mixtures with water.
- Gaseous hydrogen chloride may be used with methanol.
- the slurry is then allowed to last for a sufficient amount of time (maintained) to obtain the monohydrate, preferably for about half a day.
- the slurry process is preferably carried out about room temperature to about reflux temperature of the solvents.
- Preferred combination of starting bases and solvents include Form B and ethyl acetate/ethanol/methanol/n-butanol.
- another polymorphic form of ziprasidone HCl is used for the slurry process preferred combination of solvents and starting forms include ziprasidone HCl Form F and THF and ziprasidone HCl Form E and n-butanol, preferably in mixtures with water.
- the slurry is heated for a sufficient amount of time, more preferably to at least about 40° C.
- the present invention also provides a process for preparation of Form M, but in a substantially pure form, by slow crystallization from slurry or solution of ziprasidone base in an organic solvent.
- Preferred solvents are mixtures of THF/AcOH, THF/MeOH, DMA, n-BuOH/AcOH.
- the temperature of crystallization is more than about 50° C., preferably of about 55 to about 70° C., more preferably about 55 to about 65° C., and most preferably 65 ⁇ 2° C.
- the mode of HCl addition is preferably portion-wise.
- a first portion of HCl is added until opalescence is obtained, and the mixture is stirred to induce nucleation, followed by the rest of HCl addition.
- opalescence resulting from formation of ziprasidone HCl is observed after adding ⁇ 1/10 portion of the HCl. Seeding of ziprasidone base before the HCl addition is ideal.
- a process ziprasidone HCl form M substantially free of the crystalline ziprasidone HCl characterized by a powder XRD pattern with peaks at 10.9, 17.4, 19.1, 25.0 26.0 ⁇ 0.2 degrees 2 theta is prepared by combining a solution or slurry of ziprasidone base in a solvent with less than one equivalent HCl to obtain a reaction mixture containing ziprasidone HCl, stirring or agitating the reaction mixture, adding additional HCl to obtain additional ziprasidone HCl and recovering the ziprasidone HCl form M.
- the present invention provides for ziprasidone HCl Form E.
- Ziprasidone HCl Form E is characterized by an X-Ray diffraction pattern ( FIG. 4 ) with peaks at 7.4, 13.0, 20.7, 23.4, 25.9 ⁇ 0.2 degrees 2 theta.
- Ziprasidone HCl Form E is further characterized by XRD peaks at 13.7, 20.0, 21.3, 25.2 ⁇ 0.2 degrees two-theta.
- the DSC thermogram of ziprasidone HCl Form E ( FIG. 5 ) shows endothermic peaks of about 22, 152 and 11 J/g at about 54, 94 and 132° C. respectively, which correspond to the desolvation and dehydration of ziprasidone HCl Form E.
- the melting and decomposition of ziprasidone HCl Form E starts at about 280° C.
- the water content of ziprasidone form E measured by Karl Fisher, ranges about 9.3% to about 9.6% by weight, and the weight loss measured by TGA is about 19% by weight.
- the FTIR spectrum of ziprasidone HCl form E is shown in FIG. 6 .
- Ziprasidone HCl Form E when exposed to a high relative humidity, such as for about 22 days, transforms to form M.
- Ziprasidone HCl form E transforms to amorphous form when exposed to about 10% to about 0%, more preferably about 0% relative humidity, for such as 22 days, or after heating at elevated temperature, preferably at about 80° C. overnight.
- Ziprasidone HCl Form E transforms to Form A when exposed to a relative humidity of about 20% to about 60% for about 22 days (see table 1 and 2).
- Form A is characterized by an X-Ray diffraction pattern having peaks at about 10.9, 17.4 19.1, 25.0 and 26.0 ⁇ 0.2 degrees 2 theta.
- Ziprasidone HCl novel form E may be prepared by combining ziprasidone base with aqueous HCl in acetonitrile or ethyl acetate to obtain a slurry, and allowing the slurry to last for a sufficient time to obtain Form E.
- the slurry process is preferably carried out overnight.
- the combining of HCl with ziprasidone base is preferably carried out at a temperature of about 40° C. to about 60° C., with about 50° C. being preferred.
- the slurrying after the combining is preferably carried out at a temperature of about 20° C. to about 30° C., more preferably at about room temperature.
- Ziprasidone Form E may also be obtained as a mixture with Form A by a slurry process that uses tetrahydrofuran as a solvent. Slurrying at room temperature results in the mixture, while slurrying at higher temperatures, such as above about 50° C. results substantially in Form A.
- TABLE NO. 1 Water uptake (%) and crystal form of ziprasidone HCl form E equilibrated at different relative humidities for 22 days TGA weight RH (%) loss (%) Crystal form 0 5.3 Amorphous 20 7.2 A 40 4.8 A 60 5.0 A 80 9.2 Monohydrate + A 100 51.3 Monohydrate + A + amorphous
- the present invention provides for ziprasidone HCl Form F.
- Ziprasidone HCl Form F is characterized by an XRD pattern ( FIG. 7 ) with peaks at 11.0, 18.1, 19.5, 21.9 ⁇ 0.2 degrees 2 theta.
- Ziprasidone HCl Form F is further characterized by XRD peaks at 14.9, 24.9, 26.1 ⁇ 0.2 degrees 2 theta.
- Ziprasidone HCl Form F has a DSC thermogram ( FIG. 8 ) which shows an about a 71 J/g endothermic peak at about 85° C., corresponding to the dehydration of the ziprasidone HCl Form F. At about 280° C., ziprasidone HCl Form F starts to melt and decompose.
- the water content and the weight loss by TGA of the sample may range of about 2.6% to about 16% by weight.
- ziprasidone HCl Form F When ziprasidone HCl Form F is equilibrated at relative humidity of about 0% to about 100%, it retains its crystal form. Ziprasidone HCl Form F, after being heated overnight at about 80° C., has very low water content (0.8%), but still retains its original crystal form (see tables 3 and 4). In the range of relative humidity of about 20% to about 60%, the water content equilibrates around about 4.0% to about 4.5%, which indicates that Form F may be a stable monohydrate when kept in the humidity range of about 20% to about 60% RH.
- Ziprasidone HCl novel Form F may be prepared by combining ziprasidone base with aqueous HCl in tetrahydrofuran, methylethylketone or dimethylacetamide to obtain a slurry, and allowing the slurry to last for a sufficient time to obtain Form F.
- the slurry may be diluted by addition of water.
- the combining step is preferably carried out at elevated temperature, more preferably of about 50° C. to about 70° C., most preferably at about 60° C.
- the slurrying after the combining is preferably carried out at a temperature of about 20° C. to about 30° C., more preferably at about room temperature.
- Form F may be used for the preparation of Form M, by combining ziprasidone HCl Form F, THF and water, heating the slurry to about 50° C., cooling the slurry to room temperature, and maintaining for a sufficient time to obtain Form M.
- the present invention provides for amorphous form of ziprasidone HCl.
- Amorphous ziprasidone HCl has an X-Ray diffraction pattern as substantially depicted in FIG. 1 , in which reflection peaks are absent (halo-like pattern). Endothermic peaks are absent from the DSC thermogram of amorphous ziprasidone HCl ( FIG. 2 ).
- the FTIR spectrum of amorphous ziprasidone HCl is substantially depicted in FIG. 3 .
- Amorphous form of ziprasidone HCl may be prepared by placing Form E in a dessicator (dry chamber) having low humidity for a sufficient time to obtain amorphous form.
- ziprasidone Form E is put in a dessicator having about 0% relative humidity for about 18 days.
- Ziprasidone HCl amorphous may be prepared by drying ziprasidone HCl form E at an elevated temperature, preferably of about 80 to about 105° C., for a sufficient period of time, preferably of about 5 to about 30 hours, more preferably overnight ( ⁇ 15 hours). Ziprasidone HCl amorphous may also be prepared by exposing ziprasidone HCl form E to low relative humidity, preferably about 0%, for a sufficient period, preferably a time of about 1-3 weeks, more preferably for about 3 weeks.
- Ziprasidone hydrochloride amorphous may also be prepared by treating the slurry of ziprasidone base in MEK or mono-chlorobenzene with gaseous HCl.
- the present invention provides for ziprasidone HCl Form G.
- Ziprasidone HCl Form G has an XRPD diffraction pattern with preferred peaks at 9.0, 20.6, 22.7, 25.0, 27.0 ⁇ 0.2 degrees 2 theta, and other peaks at 11.3, 12.5, 13.9, 15.6, 21.5, 23.5, 25.8, 28.0, 31.5 ⁇ 0.2 degrees two-theta.
- Ziprasidone HCl Form G may have a water content of about 5% to about 12%. Ziprasidone HCl Form G may be a dihydrate (about 7.4% stoichiometric value for the dihydrate) or a trihydrate (about 10.7% stoichiometric value for the trihydrate). Ziprasidone HCl Form G is sparingly soluble in methanol, hence the water determination by Karl Fisher is carried out for more than 30 minutes in order to ensure that all the material is dissolved and all the water is analyzed.
- Ziprasidone HCl Form G may be prepared by introducing HCl gas into a mixture of ziprasidone base in ethyl acetate, ethyl lactate, carbon tetrachloride, di-isopropyl-ether and mixtures thereof to obtain a slurry of ziprasidone HCl, and allowing the slurry to last for a sufficient time. The slurry is preferably stirred. When ethyl acetate is used in the absence of an ether, the result may be a mixture of Form G with Form F.
- the resulting wet product may be separated by techniques known in the art such as filtration, and may be dried, preferably at a temperature of about 40° C. to about 60° C. for about half a day.
- the present invention provides for ziprasidone HCl Form I.
- Ziprasidone HCl Form I is characterized by an XRD pattern with peaks at 15.8, 16.2, 18.9, 23.8, 27.0 ⁇ 0.2 degrees 2 theta, and other peaks at 10.5, 11.3, 21.1, 24.8, 26.0 ⁇ 0.2 degrees two-theta.
- Ziprasidone HCl Form I may be prepared by heating ziprasidone HCl Form G, preferably a ziprasidone Form G obtained from a slurry in di-iso-propyl ether. The heating is preferably carried out at a temperature of about 40° C. to about 60° C. for about half a day
- the polymorphic forms of the present invention are preferably used with particle size up to 100 microns in light of low solubility of ziprasidone HCl in water.
- Ziprasidone HCl anhydrous may be prepared by drying ziprasidone HCl Form M, for example by exposing the material to low relative humidity, preferably about 0% relative humidity, for a sufficient period, preferably for about 1-3 weeks, more preferably for about 3 weeks.
- the present invention also provides for ziprasidone HCl form J.
- Ziprasidone HCl Form J is characterized by XRD peaks at 9.1, 19.1, 25.7, 26.3, 26.9 ⁇ 0.2 degrees 2 theta, and other less characteristic peaks at 11.9, 21.4, 23.4, 30.7, 32.2 ⁇ 0.2 degrees two-theta.
- Form J has an FTIR spectrum as substantially depicted in FIGS. 18 to 20 .
- the present invention also provides for ziprasidone HCl Form J with a water content of about 24%.
- Ziprasidone HCl Form J may be obtained by slurry of ziprasidone base in a C 5 to C 12 hydrocarbon, preferably toluene. A few hours of slurrying is sufficient after combining of HCl with ziprasidone base to obtain the slurry. Ziprasidone HCl Form J may then be recovered for example by solvent removal.
- the present invention also provides for ziprasidone HCl Form E1.
- Ziprasidone HCl Form E1 is characterized by XRD peaks at 7.5, 13.0, 21.2, 23.4 and 26.0 ⁇ 0.2 degrees 2 theta, and other less characteristic peaks at 10.9, 16.2, 20.8, 25.4, 30.3 and 34.8 ⁇ 0.2 degrees two-theta.
- Ziprasidone HCl Form E1 has an FTIR spectrum as substantially depicted in FIGS. 22 to 24 .
- the present invention also provides for ziprasidone HCl Form E1 with a water content of about 6% to about 8%.
- Ziprasidone HCl Form E1 may be prepared by removing solvent from ziprasidone HCl Form J. Such removal may be done by drying Form J at elevated temperature, and/or under ambient or reduced pressure. A dry nitrogen atmosphere is preferred with a temperature of about 30° C. to about 50° C., with about 40° C. being preferred.
- a slurry is most effective when the solids of the heterogeneous mixture are in substantial contact with the solvent.
- the efficiency of the slurry process often decreases due to a decrease in contact.
- a force such as stirring, agitating to disperse the solid.
- Even when the solids have not settled down, bringing of movement in the solvent may even further increase the efficiency of the slurry process.
- the slurry may dry up due to for example evaporation of the solvents.
- additional amounts of a solvent may be added (same or different solvent), preferably followed by stirring, to obtain a slurry.
- ziprasidone may be recovered from the slurry by conventional techniques in the art such as decanting, filtration and centrifugation.
- compositions of the present invention contain crystalline ziprasidone HCl, such as one of those disclosed herein, or ziprasidone HCl amorphous, optionally in mixture with other form(s) of ziprasidone.
- the pharmaceutical formulations of the present invention may contain one or more excipients. Excipients are added to the formulation for a variety of purposes.
- Diluents increase the bulk of a solid pharmaceutical composition, and may make a pharmaceutical dosage form containing the composition easier for the patient and care giver to handle.
- Diluents for solid compositions include, for example, microcrystalline cellulose (e.g. Avicel®), microfine cellulose, lactose, starch, pregelatinized starch, calcium carbonate, calcium sulfate, sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, polymethacrylates (e.g. Eudragit®), potassium chloride, powdered cellulose, sodium chloride, sorbitol and talc.
- microcrystalline cellulose e.g. Avicel®
- microfine cellulose lactose
- starch pregelatinized starch
- calcium carbonate calcium sulfate
- sugar dextrates
- dextrin
- Solid pharmaceutical compositions that are compacted into a dosage form, such as a tablet may include excipients whose functions include helping to bind the active ingredient and other excipients together after compression.
- Binders for solid pharmaceutical compositions include acacia, alginic acid, carbomer (e.g. carbopol), carboxymethylcellulose sodium, dextrin, ethyl cellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose (e.g. Klucel®), hydroxypropyl methyl cellulose (e.g. Methocel®), liquid glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates, povidone (e.g. Kollidon®, Plasdone®), pregelatinized starch, sodium alginate and starch.
- carbomer e.g. carbopol
- carboxymethylcellulose sodium, dextrin ethyl cellulose
- gelatin
- the dissolution rate of a compacted solid pharmaceutical composition in the patient's stomach may be increased by the addition of a disintegrant to the composition.
- Disintegrants include alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium (e.g. Ac-Di-Sol®, Primellose®), colloidal silicon dioxide, croscarmellose sodium, crospovidone (e.g. Kollidon®, Polyplasdone®), guar gum, magnesium aluminum silicate, methyl cellulose, microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate, sodium starch glycolate (e.g. Explotab®) and starch.
- alginic acid include alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium (e.g. Ac-Di-Sol®, Primellose®), colloidal silicon dioxide, croscarmellose sodium, crospovidone (e.g. Kollidon®, Polyplasdone®
- Glidants can be added to improve the flowability of a non-compacted solid composition and to improve the accuracy of dosing.
- Excipients that may function as glidants include colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc and tribasic calcium phosphate.
- a dosage form such as a tablet
- the composition is subjected to pressure from a punch and dye.
- Some excipients and active ingredients have a tendency to adhere to the surfaces of the punch and dye, which can cause the product to have pitting and other surface irregularities.
- a lubricant can be added to the composition to reduce adhesion and ease the release of the product from the dye.
- Lubricants include magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc and zinc stearate.
- Flavoring agents and flavor enhancers make the dosage form more palatable to the patient.
- Common flavoring agents and flavor enhancers for pharmaceutical products include maltol, vanillin, ethyl vanillin, menthol, citric acid, fumaric acid, ethyl maltol and tartaric acid.
- Solid and liquid compositions may also be dyed using any pharmaceutically acceptable colorant to improve their appearance and/or facilitate patient identification of the product and unit dosage level.
- liquid pharmaceutical compositions of the present invention ziprasidone and any other solid excipients are dissolved or suspended in a liquid carrier such as water, vegetable oil, alcohol, polyethylene glycol, propylene glycol or glycerin.
- a liquid carrier such as water, vegetable oil, alcohol, polyethylene glycol, propylene glycol or glycerin.
- Liquid pharmaceutical compositions may contain emulsifying agents to disperse uniformly throughout the composition an active ingredient or other excipient that is not soluble in the liquid carrier.
- Emulsifying agents that may be useful in liquid compositions of the present invention include, for example, gelatin, egg yolk, casein, cholesterol, acacia, tragacanth, chondrus, pectin, methyl cellulose, carbomer, cetostearyl alcohol and cetyl alcohol.
- Liquid pharmaceutical compositions of the present invention may also contain a viscosity enhancing agent to improve the mouth-feel of the product and/or coat the lining of the gastrointestinal tract.
- a viscosity enhancing agent include acacia, alginic acid bentonite, carbomer, carboxymethylcellulose calcium or sodium, cetostearyl alcohol, methyl cellulose, ethylcellulose, gelatin guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, maltodextrin, polyvinyl alcohol, povidone, propylene carbonate, propylene glycol alginate, sodium alginate, sodium starch glycolate, starch tragacanth and xanthan gum.
- Sweetening agents such as sorbitol, saccharin, sodium saccharin, sucrose, aspartame, fructose, mannitol and invert sugar may be added to improve the taste.
- Preservatives and chelating agents such as alcohol, sodium benzoate, butylated hydroxy toluene, butylated hydroxyanisole and ethylenediamine tetraacetic acid may be added at levels safe for ingestion to improve storage stability.
- a liquid composition may also contain a buffer such as gluconic acid, lactic acid, citric acid or acetic acid, sodium gluconate, sodium lactate, sodium citrate or sodium acetate. Selection of excipients and the amounts used may be readily determined by the formulation scientist based upon experience and consideration of standard procedures and reference works in the field.
- a buffer such as gluconic acid, lactic acid, citric acid or acetic acid, sodium gluconate, sodium lactate, sodium citrate or sodium acetate.
- the solid compositions of the present invention include powders, granulates, aggregates and compacted compositions.
- the dosages include dosages suitable for oral, buccal, rectal, parenteral (including subcutaneous, intramuscular, and intravenous), inhalant and ophthalmic administration. Although the most suitable administration in any given case will depend on the nature and severity of the condition being treated, the most preferred route of the present invention is oral.
- the dosages may be conveniently presented in unit dosage form and prepared by any of the methods well-known in the pharmaceutical arts.
- Dosage forms include solid dosage forms like tablets, powders, capsules, suppositories, sachets, troches and losenges, as well as liquid syrups, suspensions and elixirs.
- the dosage form of the present invention may be a capsule containing the composition, preferably a powdered or granulated solid composition of the invention, within either a hard or soft shell.
- the shell may be made from gelatin and optionally contain a plasticizer such as glycerin and sorbitol, and an opacifying agent or colorant.
- compositions and dosage forms may be formulated into compositions and dosage forms according to methods known in the art.
- a composition for tableting or capsule filling may be prepared by wet granulation.
- wet granulation some or all of the active ingredients and excipients in powder form are blended and then further mixed in the presence of a liquid, typically water, that causes the powders to clump into granules.
- the granulate is screened and/or milled, dried and then screened and/or milled to the desired particle size.
- the granulate may then be tableted, or other excipients may be added prior to tableting, such as a glidant and/or a lubricant.
- a tableting composition may be prepared conventionally by dry blending.
- the blended composition of the actives and excipients may be compacted into a slug or a sheet and then comminuted into compacted granules. The compacted granules may subsequently be compressed into a tablet.
- a blended composition may be compressed directly into a compacted dosage form using direct compression techniques.
- Direct compression produces a more uniform tablet without granules.
- Excipients that are particularly well suited for direct compression tableting include microcrystalline cellulose, spray dried lactose, dicalcium phosphate dihydrate and colloidal silica. The proper use of these and other excipients in direct compression tableting is known to those in the art with experience and skill in particular formulation challenges of direct compression tableting.
- a capsule filling of the present invention may comprise any of the aforementioned blends and granulates that were described with reference to tableting, however, they are not subjected to a final tableting step.
- the solid compositions of the present invention include powders, granulates, aggregates and compacted compositions.
- the dosages include dosages suitable for oral, buccal, rectal, parenteral (including subcutaneous, intramuscular, and intravenous), inhalant and ophthalmic administration. Although the most suitable route in any given case will depend on the nature and severity of the condition being treated, the most preferred route of the present invention is oral.
- the dosages can be conveniently presented in unit dosage form and prepared by any of the methods well-known in the pharmaceutical arts.
- the dosage of GEODON may be used as a guidance.
- the oral dosage form of the present invention is preferably in the form of an oral capsule having a dosage of about 10 mg to about 160 mg, more preferably of about 20 mg to about 80 mg, and most preferably capsules of 20, 40, 60 and 80 mg.
- X-Ray powder diffraction data were obtained using by method known in the art using a SCINTAG powder X-Ray diffractometer model X'TRA equipped with a solid state detector. Copper radiation of 1.5418 ⁇ was used. A round aluminum sample holder with round zero background quartz plate, with cavity of 25(diameter)*0.5(dept) mm.
- DSC analysis was done using a Mettler 821 Star e .
- the weight of the samples was about 5 mg; the samples were scanned at a rate of 10° C./min from 30° C. to 320° C.
- the oven was constantly purged with nitrogen gas at a flow rate of 40 ml/min. Standard 40 ⁇ l aluminum crucibles covered by lids with 3 holes were used.
- TGA analysis was done using a Mettler M3 meter.
- the weight of the samples was about 10 mg; the samples were scanned at a rate of 10° C./min from 25° C. to 200° C.
- the oven was constantly purged with nitrogen gas at a flow rate of 40 ml/min.
- Standard 70 ⁇ l alumina crucibles covered by lids with 1 hole were used.
- IR analysis was done using a Perkin Elmer SPECTRUM ONE FT-IR spectrometer in DRIFTt mode. The samples in the 4000400 cm ⁇ 1 interval were scanned 16 times with 4.0 cm ⁇ 1 resolution.
- the water content of ziprasidone HCl was measured by the methods known in the art like Karl Fisher or thermogravimetric analysis (TGA).
- TGA thermogravimetric analysis
- Ziprasidone free base used for preparations of the crystal forms of ziprasidone HCl is characterized by X-Ray peaks at 12.1, 15.2, 16.3, 18.4, 25.0 degrees 2 theta and is further characterized by XRD peaks at 5.2, 10.4, 11.3, 13.1, 21.1, 22.1.
- the ziprasidone free base has a DSC thermogram like the one shown in FIG. 13 , in which 17 and 120 J/g endothermic peaks can be seen at 92 and 220° C. The first corresponds to dehydration, the second to melting of the ziprasidone free base.
- the water content of the sample of the base is about 1.2% by weight.
- the Loss on Drying by TGA is about 2.1% by weight.
- the IR spectrum of ziprasidone free base is substantially depicted in FIG. 14 .
- the form of ziprasidone is referred to as Form B.
- One of skill in the art would appreciate that the processes of the present invention may use other forms of ziprasidone base as starting material.
- Ziprasidone base for the experiments below was prepared according to the procedure “EXPERIMENT” in U.S. Pat. No. 5,312,925, column 4.
- the water content of the base was 1.2% (Karl Fisher).
- Ziprasidone base (50 g) and toluene (250 ml) were charged into a 0.5 L three necked flask. The obtained slurry was heated at 85° C. for 2 hours. The hot slurry was filtrated and the solid was washed with methanol. The solid was dried in air-circulated oven at 50° C. to afford the dried Ziprasidone base form B (by XRD) (45.39 g).
- Aqueous HCl (37%) (10 ml) was added to a slurry of ziprasidone base Form B (10 g) in acetonitrile (200 ml) at reflux. After the addition, the slurry was heated over night. A solid was filtered and washed with acetonitrile. After drying at 50° C. for ⁇ 16 hours, ziprasidone HCl Form E was obtained (12.71 g) (The water content was 9.25% by K.F. and the loss on drying by TGA is 18.8%), as confirmed by XRD.
- a slurry of ziprasidone base form B (10 g) in ethyl acetate (100 ml) was heated at reflux without complete dissolution. The slurry was then cooled. When the temperature was about 50° C., aqueous HCl (37%) (10 ml) was added, and the slurry was diluted by addition of ethyl acetate (100 ml). The slurry was stirred for ⁇ 16 hours. A solid was filtered and washed with ethyl acetate. The wet solid was ziprasidone HCl Form E, as confirmed by XRD. The wet solid was dried at 50° C. The dried solid had a water content of 9.62% (by K.F.) and a loss on drying of 19% (by TGA). The dried solid was Form E, as confirmed by XRD.
- Aqueous HCl (37%) (10 ml) was added drop-wise to a hot slurry of ziprasidone base Form B (10 g) in methylethylketone (MEK) (200 ml). The slurry was stirred at room temperature over night. A solid was filtered and washed with MEK. The wet solid was ziprasidone HCl Form F. The wet solid was dried at 50° C. for two days. The dried product was ziprasidone HCl Form F (10.62 g) (The water content was 3.87% by K.F. and the loss on drying is 4.1% by TGA), as confirmed by XRD.
- Aqueous hydrochloric acid (37%) (910 ml) was added to a hot slurry of ziprasidone base (10 g) in tetrahydrofuran (THF) (200 ml). The slurry was stirred at room temperature for about 16 hours. A solid was filtered, washed with THF and dried in an oven at 50° C. for two days. The wet and the dried solid samples were ziprasidone HCl Form F (The water content was 3.63%), as confirmed by XRD.
- Ziprasidone base (10 g) was dissolved in dimethylacetamide (100 ml) at ⁇ 95° C. The solution was cooled to 70° C. and aqueous HCl (37%) (10 ml) was added, resulting in precipitation and formation of a slurry. The slurry was then cooled to room temperature, followed by addition of water (100 ml). Stirring was continued for 1 hour at room temperature, followed by filtration, and washing of a solid material obtained from filtration with water. The wet solid was dried at 50° C. for about 16 hours to a dry solid (7.1 g). The wet and the dried solid were ziprasidone HCl Form F in mixture with Form M (The water content of the dried solid is 4.17% by K.F.), as confirmed by XRD.
- Ziprasidone hydrochloride Form E (4.05 g) was heated at 80-105° C. in an oven for about 16 hours. The solid after heating was ziprasidone HCl amorphous (3.33 g) (The water content was 1.21% by K.F.), as confirmed by XRD.
- Ziprasidone base (10 g) was taken in dimethylcarbonate (DMC) (100 ml) and the mixture was heated at ⁇ 90° C. Aqueous HCl (37%) (10 ml) was added, resulting in a sticky material. Additional amount of DMC (100 ml), and methanol (50 ml), were added, resulting in a slurry. The slurry was stirred at room temperature over night. A solid was filtered and washed with DMC, and subsequently dried at 50° C. overnight. The wet and the dried solids were ziprasidone HCl monohydrate, as confirmed by XRD. The water content of the dried solid by K.F. is 4.78%.
- drying was carried out in an air-circulated oven.
- the pressure was atmospheric pressure.
- Ziprasidone base Form B (10 g) was added to ethyl-lactate (50 ml) and the slurry obtained was cooled to 5° C. HCl(g) was bubbled through the above slurry and ether (150 ml) was added. The slurry was stirred over night at room temperature, filtrated and washed with ether. The wet material was dried at 50° C. in an air-circulated oven and ziprasidone HCl Form G was obtained.
- Ziprasidone base Form B (5 g) was added to carbon-tetrachloride (50 ml) and HCl(g) was bubbled until pH 1 was reached. The temperature rose to ⁇ 40° C. The slurry was stirred at room temperature for 3 hours and filtrated. The solid was dried in an air-circulated oven at 50° C. for 17 hours. The wet and the dried solid both were ziprasidone HCl Form G.
- Ziprasidone base Form B (10 g) was added to di-iso-propyl-ether (200 ml) and the slurry was stirred at room temperature; through the slurry HCl(g) was bubbled while the temperature rose to ⁇ 50° C. The slurry was stirred at room temperature over-night, the solid was filtrated and washed with di-iso-propyl-ether. The wet solid gave ziprasidone HCl Form G. Drying of the wet solid in an air-circulated oven at 50° C. for ⁇ 16 h gave ziprasidone HCl Form I.
- Ziprasidone base Form B (10 g) was added to ethyl-acetate (200 ml) and HCl(g) was bubbled through the slurry; the temperature rose to ⁇ 35° C. The slurry was stirred at room temperature for 3 hours and the solid was filtrated, washed with ethyl-acetate and dried for ⁇ 16 h in an air-circulated oven at 45° C. The wet and dried solids both gave a mixture of ziprasidone HCl Form G and F.
- ziprasidone base (Form B) (10 g) in methanol (200 ml) at 60° C. was added concentrated HCl (10 ml); the slurry was then stirred at room temperature for about 16 hours. A solid was filtrated, washed with methanol (2 ⁇ 10 ml) and dried at 50° C. in an air-circulated oven for 2 days.
- the product was ziprasidone HCl Form M (K.F. 4.26%).
- a slurry of ziprasidone base (Form B) (10 g) in n-butanol (250 ml) was heated to 60° C. While maintaining the temperature, concentrated HCl was added (10 ml). The reaction mixture was than stirred at room temperature for about 16 hours. A solid was filtrated, washed with n-butanol (2 ⁇ 20 ml) and dried for about 16 hours at 50° C. in an air-circulated oven. The dried solid was ziprasidone HCl Form M (K.F. 4.12%).
- Ziprasidone HCl Form E (2 g) was heated in n-butanol (200 ml) and water (40 ml) at 85° C.; complete dissolution was not obtained. More water was added (20 ml) and the slurry was stirred at 90° C. for 1.5 hours. A solid was filtrated from the hot slurry, washed with n-butanol/water (4 ml 3:1) and dried. From the filtrate a solid was obtained upon cooling to 10° C. This material was filtrated, washed and dried in the same conditions. Both dried solids were ziprasidone HCl Form M.
- Aqueous HCl was drop-wise added over 10 minutes, to a slurry of ziprasidone base (5 g) in toluene (100 ml) at room temperature. The obtained mixture was stirred at room temperature for 3 hours, and then the solvent was evaporated under vacuum. The solid obtained after the toluene evaporation was ziprasidone HCl Form J.
- the above material (ZPR HCl form J form Example 20) was dried by maintaining it at 40° C. and under nitrogen atmosphere over night, followed by additional drying with a rotary evaporator.
- the dried material collected after the two drying stages was ziprasidone HCl Form E1 (water content by K.F. ⁇ 6% and ⁇ 8% respectively).
- the above material (ZPR HCl form J) was dried by maintaining it at 40° C. and under nitrogen over night, followed by an additional drying operation on a rotary evaporator.
- the dried material collected in the two drying stages was ziprasidone HCl Form E1 (water content by K.F. 6% and 7.8% respectively).
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cephalosporin Compounds (AREA)
Abstract
Description
- This application is a divisional of U.S. patent application Ser. No. 10/860,926, filed Jun. 3, 2004, claims the benefit of U.S. provisional application Ser. No. 60/475,806, filed Jun. 3, 2003; U.S. provisional application Ser. No. 60/487,913, filed Jul. 16, 2003; U.S. provisional application Ser. No. 60/494,970, filed Aug. 13, 2003; U.S. provisional application Ser. No. 60/528,346, filed Dec. 9, 2003, and U.S. provisional application Ser. No. 60/571,997; filed May 17, 2004, the contents of all of which are incorporated herein.
- The present invention relates to the solid state chemistry of ziprasidone HCl.
-
- The preparation of ziprasidone base is disclosed in U.S. Pat. No. 4,831,031 (example 16). Preparation of ziprasidone base is also disclosed in U.S. Pat. No. 5,312,925. A process for preparation of ziprasidone HCl monohydrate having a mean particle size equal to or less than about 85 microns is also disclosed in U.S. Pat. No. 6,150,366 and
EP 0 965 343 A2. - Ziprasidone has been marketed under the name GEODON as an oral capsule and as an injectable drug. GEODON capsules contain the monohydrate hydrochloride salt of ziprasidone, and come in 20, 40, 60 and 80 mg dosage forms. GEODON for injection contains a lyophilized form of ziprasidone mesylate trihydrate, and contains 20 mg base equivalent of ziprasidone. The mesylate salts of ziprasidone, including monohydrate and trihydrate, are disclosed in U.S. Pat. Nos. 6,110,918 and 5,245,765.
- The present invention relates to the solid state physical properties of ziprasidone HCl.
- These properties can be influenced by controlling the conditions under which ziprasidone HCl is obtained in solid form. Solid state physical properties include, for example, the flowability of the milled solid. Flowability affects the ease with which the material is handled during processing into a pharmaceutical product. When particles of the powdered compound do not flow past each other easily, a formulation specialist must take that fact into account in developing a tablet or capsule formulation, which may necessitate the use of glidants such as colloidal silicon dioxide, talc, starch or tribasic calcium phosphate.
- Another important solid state property of a pharmaceutical compound is its rate of dissolution in aqueous fluid. The rate of dissolution of an active ingredient in a patient's stomach fluid can have therapeutic consequences since it imposes an upper limit on the rate at which an orally-administered active ingredient can reach the patient's bloodstream. The rate of dissolution is also a consideration in formulating syrups, elixirs and other liquid medicaments. The solid state form of a compound may also affect its behavior on compaction and its storage stability.
- These practical physical characteristics are influenced by the conformation and orientation of molecules in the unit cell, which defines a particular polymorphic form of a substance. These conformational and orientational factors in turn result in particular intramolecular interactions and intermolecular interactions with adjacent molecules that influence the macroscopic properties of the bulk compound. A particular polymorphic form may give rise to distinct spectroscopic properties that may be detectable by powder X-Ray diffraction, solid state 13C NMR spectrometry and infrared spectrometry. The polymorphic form may also give rise to thermal behavior different from that of the amorphous material or another polymorphic form. Thermal behavior is measured in the laboratory by such techniques as capillary melting point, thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) and can be used to distinguish some polymorphic forms from others.
- Ziprasidone HCl hemihydrate is disclosed in U.S. Pat. No. 4,831,031, Example 16 (column 13, line 13). A ziprasidone HCl monohydrate (herein designated Form M) is disclosed in U.S. Pat. No. 5,312,925 and
EP 0 586 181 A1. Form M is characterized by XRD, IR and water content. It is reported that the water content of Form M ranges from 3.8 to 4.5% by weight. Ziprasidone HCl Form M is prepared from ziprasidone base anhydrous. - The discovery of new polymorphic forms of a pharmaceutically useful compound provides a new opportunity to improve the performance characteristics of a pharmaceutical product. It enlarges the repertoire of materials that a formulation scientist has available for designing, for example, a pharmaceutical dosage form of a drug with a targeted release profile or other desired characteristic. There is a need in the art for additional polymorphic forms of ziprasidone HCl.
- In one aspect, the present invention provides a crystalline form of ziprasidone HCl (Form E), wherein the crystalline form is characterized by a powder XRD pattern with peaks at 7.4, 13.0, 20.7, 23.4, 25.9±0.2
degrees 2 theta. - In another aspect, the present invention provides a process for preparing ziprasidone HCl Form E, comprising:
- a) combining aqueous HCl with ziprasidone base in the presence of ethyl acetate or acetonitrile to obtain a slurry;
- b) maintaining the slurry to obtain ziprasidone HCl; and
- c) recovering the ziprasidone HCl.
- In another aspect, the present invention provides a crystalline form of ziprasidone HCl, wherein the crystalline form is a trihydrate.
- In another aspect, the present invention provides a process for preparing ziprasidone HCl Form E in a mixture with a crystalline ziprasidone HCl having an X-Ray diffraction pattern having peaks at about 10.9, 17.4 and 19.1±0.2
degrees 2 theta, comprising: - a) combining aqueous HCl with ziprasidone base in the presence of tetrahydrofuran to obtain a slurry;
- b) maintaining the slurry to obtain ziprasidone HCl; and
- c) recovering the ziprasidone HCl mixture.
- In another aspect, the present invention provides a crystalline form of ziprasidone HCl (Form F), wherein the crystalline form is characterized by a powder XRD pattern with peaks at 11.0, 18.1, 19.5, 21.9±0.2
degrees 2 theta. - In another aspect, the present invention provides a process for preparing the ziprasidone HCl Form F, comprising:
- a) combining aqueous HCl with ziprasidone base in a solvent selected from the group consisting of methylethylketone, tetrahydrofuran and dimethylacetamide to obtain a slurry;
- b) maintaining the slurry to obtain ziprasidone HCl; and
- c) recovering the ziprasidone HCl.
- In another aspect, the present invention provides a process for preparing the ziprasidone HCl form M, comprising:
- a) heating a slurry of ziprasidone HCl in n-butanol or THF, optionally in mixture with water; and
- b) recovering the ziprasidone HCl form M.
- In another aspect, the present invention provides a process for preparing the ziprasidone HCl form M comprising:
- a) combining aqueous HCl with ziprasidone base at a temperature of at least about 40° C. in a solvent selected from the group consisting of ethanol, methanol, n-butanol, acetone, ethyl acetate, ethyl lactate, dimethyl-carbonate, optionally in a mixtures with water to obtain a slurry,
- b) maintaining the slurry to obtain the ziprasidone HCl form M; and
- c) recovering the ziprasidone HCl form M.
- In another aspect, the present invention provides a process for preparing the ziprasidone HCl form M comprising:
- a) contacting gaseous hydrogen chloride with ziprasidone base in methanol to obtain a slurry of ziprasidone hydrochloride in methanol;
- b) maintaining the slurry to obtain the ziprasidone HCl form M; and
- c) recovering the ziprasidone HCl form M.
- In another aspect, the present invention provides a process for preparing the ziprasidone HCl form M substantially free of the crystalline ziprasidone HCl characterized by a powder XRD pattern with peaks at 10.9, 17.4, 19.1, 25.0, 26.0±0.2
degrees 2 theta comprising: - a) combining a solution or slurry of ziprasidone base in a solvent with less than one equivalent HCl to obtain a reaction mixture containing ziprasidone HCl;
- b) stirring or agitating the reaction mixture;
- c) adding additional HCl to obtain additional ziprasidone HCl; and
- d) recovering the ziprasidone HCl form M.
- In another aspect, the present invention provides for amorphous form of ziprasidone HCl.
- In another aspect, the present invention provides a process for preparing amorphous form comprising slurrying ziprasidone base with methyl ethyl ketone or mono-chloro benzene with gaseous hydrochloride.
- In another aspect, the present invention provides a crystalline form of ziprasidone HCl (Form G), wherein the crystalline form is characterized by a powder XRD pattern with peaks at 9.0, 20.6, 22.7, 25.0, 27.0±0.2
degrees 2 theta. - In another aspect, the present invention provides a process for preparing ziprasidone HCl Form G comprising:
- a) combining gaseous HCl with a mixture of ziprasidone base in a solvent selected from the group consisting of carbon tetrachloride, di-isopropyl-ether, ethyl acetate, ethyl lactate and mixtures thereof to obtain a slurry of ziprasidone HCl;
- b) maintaining the slurry to obtain ziprasidone HCl Form G; and
- c) recovering the ziprasidone HCl.
- In another aspect, the present invention provides a process for preparing a mixture of the ziprasidone HCl of Form F and ziprasidone HCl Form G comprising:
- a) combining gaseous HCl with a mixture of ziprasidone base in ethyl acetate to obtain a slurry of ziprasidone HCl;
- b) maintaining the slurry to obtain ziprasidone HCl; and
- c) recovering the mixture.
- In another aspect, the present invention provides a crystalline form of ziprasidone HCl (Form I), wherein the crystalline form has an XRD pattern with peaks at 15.8, 16.2, 18.9, 23.8, 27.0±0.2
degrees 2 theta, - In another aspect, the present invention provides a crystalline form of ziprasidone HCl (Form J), wherein the crystalline form is characterized by a powder XRD pattern with peaks at 9.1, 19.1, 25.7, 26.3, 26.9±0.2
degrees 2 theta. - In another aspect, the present invention provides a process for preparing ziprasidone HCl Form J comprising:
- a) combining ziprasidone base with HCl to obtain a slurry of ziprasidone HCl in a C5 to C12 hydrocarbon;
- b) maintaining the slurry to obtain the crystalline ziprasidone HCl; and
- c) recovering the ziprasidone HCl.
- In another aspect; the present invention provides a crystalline form of ziprasidone HCl, wherein the crystalline form has a water content of about 24% by LOD.
- In another aspect, the present invention provides a crystalline from of ziprasidone HCl (Form E1), wherein the crystalline form is characterized a powder XRD pattern with peaks at 7.5, 13.0, 21.2, 23.4 and 26.0±0.2
degrees 2 theta. - In another aspect, the present invention provides a process for preparing ziprasidone HCl Form E1 comprising drying the ziprasidone HCl Form J.
- In another aspect, the present invention provides a crystalline form of ziprasidone, wherein the crystalline form has a water content of about 6% to about 8%.
- In another aspect, the present invention provides a pharmaceutical composition and method of treating a patient suffering from schizophrenia.
-
FIG. 1 is an X-Ray powder diffractogram of amorphous ziprasidone HCl. -
FIG. 2 is a DSC thermogram of amorphous ziprasidone HCl. -
FIG. 3 is an IR spectrum of ziprasidone HCl amorphous. -
FIG. 4 is an X-Ray powder diffractogram of ziprasidone HCl form E. -
FIG. 5 is a DSC thermogram of ziprasidone HCl form E. -
FIG. 6 is an IR spectrum of ziprasidone HCl form E. -
FIG. 7 is an X-Ray powder diffractogram of ziprasidone HCl form F. -
FIG. 8 is a DSC thermogram of ziprasidone HCl form F. -
FIG. 9 is an IR spectrum of ziprasidone HCl form F. -
FIG. 10 is a DSC thermogram of ziprasidone HCl Form M. -
FIG. 11 is an IR spectrum of ziprasidone HCl Form M. -
FIG. 12 is an X-Ray powder diffractogram of ziprasidone Base. -
FIG. 13 is a DSC thermogram of ziprasidone Base. -
FIG. 14 is an IR spectrum of ziprasidone Base. -
FIG. 15 is an X-Ray powder diffractogram of ziprasidone HCl Form G. -
FIG. 16 is an X-Ray powder diffractogram of ziprasidone HCl Form I. -
FIG. 17 is an X-Ray powder diffractogram of ziprasidone HCl Form J. -
FIG. 18 is an FTIR spectrum of ziprasidone HCl Form J. -
FIG. 19 is an FTIR spectrum of ziprasidone HCl Form J. -
FIG. 20 is an FTIR spectrum of ziprasidone HCl Form J. -
FIG. 21 is an X-Ray powder diffractogram of ziprasidone HCl Form E1. -
FIG. 22 is an FTIR spectrum of ziprasidone HCl Form E1. -
FIG. 23 is an FTIR spectrum of ziprasidone HCl Form E1. -
FIG. 24 is an FTIR spectrum of ziprasidone HCl Form E1. - As used herein, the term slurry refers to a heterogeneous mixture.
- As used herein, the term reduced pressure refers to a pressure below about 1 atm, more preferably below about 100 mmHg.
- The present invention provides for obtaining ziprasidone HCl Form M from ziprasidone base, or other forms of ziprasidone hydrochloride. Ziprasidone base, such as form B, but not limited to this form, is combined with aqueous hydrochloric acid and slurried in solvents such as methanol, ethanol, n-butanol, ethyl acetate, ethyl lactate, acetone, dimethyl carbonate, optionally in mixtures with water. Gaseous hydrogen chloride may be used with methanol. The slurry is then allowed to last for a sufficient amount of time (maintained) to obtain the monohydrate, preferably for about half a day. The slurry process is preferably carried out about room temperature to about reflux temperature of the solvents. Preferred combination of starting bases and solvents include Form B and ethyl acetate/ethanol/methanol/n-butanol. In another embodiment, rather than starting with ziprasidone base, another polymorphic form of ziprasidone HCl is used for the slurry process preferred combination of solvents and starting forms include ziprasidone HCl Form F and THF and ziprasidone HCl Form E and n-butanol, preferably in mixtures with water. Preferably, the slurry is heated for a sufficient amount of time, more preferably to at least about 40° C.
- The present invention also provides a process for preparation of Form M, but in a substantially pure form, by slow crystallization from slurry or solution of ziprasidone base in an organic solvent. Preferred solvents are mixtures of THF/AcOH, THF/MeOH, DMA, n-BuOH/AcOH. The temperature of crystallization is more than about 50° C., preferably of about 55 to about 70° C., more preferably about 55 to about 65° C., and most preferably 65±2° C. The mode of HCl addition is preferably portion-wise.
- In one embodiment, a first portion of HCl is added until opalescence is obtained, and the mixture is stirred to induce nucleation, followed by the rest of HCl addition. Typically, opalescence resulting from formation of ziprasidone HCl is observed after adding ˜ 1/10 portion of the HCl. Seeding of ziprasidone base before the HCl addition is ideal.
- In one embodiment, A process ziprasidone HCl form M substantially free of the crystalline ziprasidone HCl characterized by a powder XRD pattern with peaks at 10.9, 17.4, 19.1, 25.0 26.0±0.2
degrees 2 theta is prepared by combining a solution or slurry of ziprasidone base in a solvent with less than one equivalent HCl to obtain a reaction mixture containing ziprasidone HCl, stirring or agitating the reaction mixture, adding additional HCl to obtain additional ziprasidone HCl and recovering the ziprasidone HCl form M. - In another aspect, the present invention provides for ziprasidone HCl Form E. Ziprasidone HCl Form E is characterized by an X-Ray diffraction pattern (
FIG. 4 ) with peaks at 7.4, 13.0, 20.7, 23.4, 25.9±0.2degrees 2 theta. Ziprasidone HCl Form E is further characterized by XRD peaks at 13.7, 20.0, 21.3, 25.2±0.2 degrees two-theta. The DSC thermogram of ziprasidone HCl Form E (FIG. 5 ) shows endothermic peaks of about 22, 152 and 11 J/g at about 54, 94 and 132° C. respectively, which correspond to the desolvation and dehydration of ziprasidone HCl Form E. According to the thermogram, the melting and decomposition of ziprasidone HCl Form E starts at about 280° C. The water content of ziprasidone form E, measured by Karl Fisher, ranges about 9.3% to about 9.6% by weight, and the weight loss measured by TGA is about 19% by weight. - This corresponds approximately to a trihydrate, which may contain solvent approximately as 1½-1⅓ solvate of acetonitrile, or ⅔-¾ solvate of ethyl acetate.
- The FTIR spectrum of ziprasidone HCl form E is shown in
FIG. 6 . - Ziprasidone HCl Form E when exposed to a high relative humidity, such as for about 22 days, transforms to form M. Ziprasidone HCl form E transforms to amorphous form when exposed to about 10% to about 0%, more preferably about 0% relative humidity, for such as 22 days, or after heating at elevated temperature, preferably at about 80° C. overnight. Ziprasidone HCl Form E transforms to Form A when exposed to a relative humidity of about 20% to about 60% for about 22 days (see table 1 and 2). Form A is characterized by an X-Ray diffraction pattern having peaks at about 10.9, 17.4 19.1, 25.0 and 26.0±0.2
degrees 2 theta. - Ziprasidone HCl novel form E may be prepared by combining ziprasidone base with aqueous HCl in acetonitrile or ethyl acetate to obtain a slurry, and allowing the slurry to last for a sufficient time to obtain Form E. The slurry process is preferably carried out overnight. The combining of HCl with ziprasidone base is preferably carried out at a temperature of about 40° C. to about 60° C., with about 50° C. being preferred. The slurrying after the combining is preferably carried out at a temperature of about 20° C. to about 30° C., more preferably at about room temperature. Ziprasidone Form E may also be obtained as a mixture with Form A by a slurry process that uses tetrahydrofuran as a solvent. Slurrying at room temperature results in the mixture, while slurrying at higher temperatures, such as above about 50° C. results substantially in Form A.
TABLE NO. 1 Water uptake (%) and crystal form of ziprasidone HCl form E equilibrated at different relative humidities for 22 days TGA weight RH (%) loss (%) Crystal form 0 5.3 Amorphous 20 7.2 A 40 4.8 A 60 5.0 A 80 9.2 Monohydrate + A 100 51.3 Monohydrate + A + amorphous -
TABLE NO. 2 Crystal form of ziprasidone HCl form E heated at 80-105° C. overnight Original Crystal form after heating crystal form at 80-105° C. overnight Form E Amorphous + form F - In another aspect, the present invention provides for ziprasidone HCl Form F. Ziprasidone HCl Form F is characterized by an XRD pattern (
FIG. 7 ) with peaks at 11.0, 18.1, 19.5, 21.9±0.2degrees 2 theta. Ziprasidone HCl Form F is further characterized by XRD peaks at 14.9, 24.9, 26.1±0.2degrees 2 theta. Ziprasidone HCl Form F has a DSC thermogram (FIG. 8 ) which shows an about a 71 J/g endothermic peak at about 85° C., corresponding to the dehydration of the ziprasidone HCl Form F. At about 280° C., ziprasidone HCl Form F starts to melt and decompose. The water content and the weight loss by TGA of the sample may range of about 2.6% to about 16% by weight. When ziprasidone HCl Form F is equilibrated at relative humidity of about 0% to about 100%, it retains its crystal form. Ziprasidone HCl Form F, after being heated overnight at about 80° C., has very low water content (0.8%), but still retains its original crystal form (see tables 3 and 4). In the range of relative humidity of about 20% to about 60%, the water content equilibrates around about 4.0% to about 4.5%, which indicates that Form F may be a stable monohydrate when kept in the humidity range of about 20% to about 60% RH. - The IR spectrum of ziprasidone HCl form F in
FIG. 9 is shown. - Ziprasidone HCl novel Form F may be prepared by combining ziprasidone base with aqueous HCl in tetrahydrofuran, methylethylketone or dimethylacetamide to obtain a slurry, and allowing the slurry to last for a sufficient time to obtain Form F. The slurry may be diluted by addition of water. The combining step is preferably carried out at elevated temperature, more preferably of about 50° C. to about 70° C., most preferably at about 60° C. The slurrying after the combining is preferably carried out at a temperature of about 20° C. to about 30° C., more preferably at about room temperature. Preferably, when the solvent is dimethylacetamide, a mixture of Form F and Form M is obtained.
TABLE NO. 3 Water uptake (%) and crystal form of ziprasidone HCl form F equilibrated at different relative humidities for 22 days TGA weight RH (%) loss (%) Crystal form 0 2.6 F 20 4.2 F 40 4.0 F 60 4.5 F 80 7.7 F 100 15.8 F -
TABLE NO. 4 Crystal form of ziprasidone HCl form F heated at 80-105° C. overnight Original Crystal form after heating % water crystal form at 80-105° C. overnight content Form F Form F 0.8 - Form F may be used for the preparation of Form M, by combining ziprasidone HCl Form F, THF and water, heating the slurry to about 50° C., cooling the slurry to room temperature, and maintaining for a sufficient time to obtain Form M.
- In another aspect, the present invention provides for amorphous form of ziprasidone HCl. Amorphous ziprasidone HCl has an X-Ray diffraction pattern as substantially depicted in
FIG. 1 , in which reflection peaks are absent (halo-like pattern). Endothermic peaks are absent from the DSC thermogram of amorphous ziprasidone HCl (FIG. 2 ). The FTIR spectrum of amorphous ziprasidone HCl is substantially depicted inFIG. 3 . - Amorphous form of ziprasidone HCl may be prepared by placing Form E in a dessicator (dry chamber) having low humidity for a sufficient time to obtain amorphous form. In a preferred embodiment, ziprasidone Form E is put in a dessicator having about 0% relative humidity for about 18 days.
- Ziprasidone HCl amorphous may be prepared by drying ziprasidone HCl form E at an elevated temperature, preferably of about 80 to about 105° C., for a sufficient period of time, preferably of about 5 to about 30 hours, more preferably overnight (˜15 hours). Ziprasidone HCl amorphous may also be prepared by exposing ziprasidone HCl form E to low relative humidity, preferably about 0%, for a sufficient period, preferably a time of about 1-3 weeks, more preferably for about 3 weeks.
- Ziprasidone hydrochloride amorphous may also be prepared by treating the slurry of ziprasidone base in MEK or mono-chlorobenzene with gaseous HCl.
- In another aspect, the present invention provides for ziprasidone HCl Form G. Ziprasidone HCl Form G has an XRPD diffraction pattern with preferred peaks at 9.0, 20.6, 22.7, 25.0, 27.0±0.2
degrees 2 theta, and other peaks at 11.3, 12.5, 13.9, 15.6, 21.5, 23.5, 25.8, 28.0, 31.5±0.2 degrees two-theta. - Ziprasidone HCl Form G may have a water content of about 5% to about 12%. Ziprasidone HCl Form G may be a dihydrate (about 7.4% stoichiometric value for the dihydrate) or a trihydrate (about 10.7% stoichiometric value for the trihydrate). Ziprasidone HCl Form G is sparingly soluble in methanol, hence the water determination by Karl Fisher is carried out for more than 30 minutes in order to ensure that all the material is dissolved and all the water is analyzed.
- Ziprasidone HCl Form G may be prepared by introducing HCl gas into a mixture of ziprasidone base in ethyl acetate, ethyl lactate, carbon tetrachloride, di-isopropyl-ether and mixtures thereof to obtain a slurry of ziprasidone HCl, and allowing the slurry to last for a sufficient time. The slurry is preferably stirred. When ethyl acetate is used in the absence of an ether, the result may be a mixture of Form G with Form F. The resulting wet product may be separated by techniques known in the art such as filtration, and may be dried, preferably at a temperature of about 40° C. to about 60° C. for about half a day.
- In another aspect, the present invention provides for ziprasidone HCl Form I. Ziprasidone HCl Form I is characterized by an XRD pattern with peaks at 15.8, 16.2, 18.9, 23.8, 27.0±0.2
degrees 2 theta, and other peaks at 10.5, 11.3, 21.1, 24.8, 26.0±0.2 degrees two-theta. Ziprasidone HCl Form I may be prepared by heating ziprasidone HCl Form G, preferably a ziprasidone Form G obtained from a slurry in di-iso-propyl ether. The heating is preferably carried out at a temperature of about 40° C. to about 60° C. for about half a day - The polymorphic forms of the present invention are preferably used with particle size up to 100 microns in light of low solubility of ziprasidone HCl in water.
- Ziprasidone HCl anhydrous may be prepared by drying ziprasidone HCl Form M, for example by exposing the material to low relative humidity, preferably about 0% relative humidity, for a sufficient period, preferably for about 1-3 weeks, more preferably for about 3 weeks.
- The present invention also provides for ziprasidone HCl form J. Ziprasidone HCl Form J is characterized by XRD peaks at 9.1, 19.1, 25.7, 26.3, 26.9±0.2
degrees 2 theta, and other less characteristic peaks at 11.9, 21.4, 23.4, 30.7, 32.2±0.2 degrees two-theta. Form J has an FTIR spectrum as substantially depicted in FIGS. 18 to 20. The present invention also provides for ziprasidone HCl Form J with a water content of about 24%. - Ziprasidone HCl Form J may be obtained by slurry of ziprasidone base in a C5 to C12 hydrocarbon, preferably toluene. A few hours of slurrying is sufficient after combining of HCl with ziprasidone base to obtain the slurry. Ziprasidone HCl Form J may then be recovered for example by solvent removal.
- The present invention also provides for ziprasidone HCl Form E1. Ziprasidone HCl Form E1 is characterized by XRD peaks at 7.5, 13.0, 21.2, 23.4 and 26.0±0.2
degrees 2 theta, and other less characteristic peaks at 10.9, 16.2, 20.8, 25.4, 30.3 and 34.8±0.2 degrees two-theta. Ziprasidone HCl Form E1 has an FTIR spectrum as substantially depicted in FIGS. 22 to 24. The present invention also provides for ziprasidone HCl Form E1 with a water content of about 6% to about 8%. - Ziprasidone HCl Form E1 may be prepared by removing solvent from ziprasidone HCl Form J. Such removal may be done by drying Form J at elevated temperature, and/or under ambient or reduced pressure. A dry nitrogen atmosphere is preferred with a temperature of about 30° C. to about 50° C., with about 40° C. being preferred.
- A slurry is most effective when the solids of the heterogeneous mixture are in substantial contact with the solvent. When the solids settle down, the efficiency of the slurry process often decreases due to a decrease in contact. Thus, one of skill in the art would appreciate that if during the slurry process the solids settle down, a force such as stirring, agitating to disperse the solid. Even when the solids have not settled down, bringing of movement in the solvent may even further increase the efficiency of the slurry process.
- One of skill in the art would appreciate that as the slurry is allowed to last for a sufficient time to obtain a particular polymorphic form, the slurry may dry up due to for example evaporation of the solvents. As the examples illustrate, additional amounts of a solvent may be added (same or different solvent), preferably followed by stirring, to obtain a slurry.
- The various forms of ziprasidone may be recovered from the slurry by conventional techniques in the art such as decanting, filtration and centrifugation.
- Pharmaceutical formulations of the present invention contain crystalline ziprasidone HCl, such as one of those disclosed herein, or ziprasidone HCl amorphous, optionally in mixture with other form(s) of ziprasidone. In addition to the active ingredient(s), the pharmaceutical formulations of the present invention may contain one or more excipients. Excipients are added to the formulation for a variety of purposes.
- Diluents increase the bulk of a solid pharmaceutical composition, and may make a pharmaceutical dosage form containing the composition easier for the patient and care giver to handle. Diluents for solid compositions include, for example, microcrystalline cellulose (e.g. Avicel®), microfine cellulose, lactose, starch, pregelatinized starch, calcium carbonate, calcium sulfate, sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, polymethacrylates (e.g. Eudragit®), potassium chloride, powdered cellulose, sodium chloride, sorbitol and talc.
- Solid pharmaceutical compositions that are compacted into a dosage form, such as a tablet, may include excipients whose functions include helping to bind the active ingredient and other excipients together after compression. Binders for solid pharmaceutical compositions include acacia, alginic acid, carbomer (e.g. carbopol), carboxymethylcellulose sodium, dextrin, ethyl cellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose (e.g. Klucel®), hydroxypropyl methyl cellulose (e.g. Methocel®), liquid glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates, povidone (e.g. Kollidon®, Plasdone®), pregelatinized starch, sodium alginate and starch.
- The dissolution rate of a compacted solid pharmaceutical composition in the patient's stomach may be increased by the addition of a disintegrant to the composition. Disintegrants include alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium (e.g. Ac-Di-Sol®, Primellose®), colloidal silicon dioxide, croscarmellose sodium, crospovidone (e.g. Kollidon®, Polyplasdone®), guar gum, magnesium aluminum silicate, methyl cellulose, microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate, sodium starch glycolate (e.g. Explotab®) and starch.
- Glidants can be added to improve the flowability of a non-compacted solid composition and to improve the accuracy of dosing. Excipients that may function as glidants include colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc and tribasic calcium phosphate.
- When a dosage form such as a tablet is made by the compaction of a powdered composition, the composition is subjected to pressure from a punch and dye. Some excipients and active ingredients have a tendency to adhere to the surfaces of the punch and dye, which can cause the product to have pitting and other surface irregularities. A lubricant can be added to the composition to reduce adhesion and ease the release of the product from the dye. Lubricants include magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc and zinc stearate.
- Flavoring agents and flavor enhancers make the dosage form more palatable to the patient. Common flavoring agents and flavor enhancers for pharmaceutical products that may be included in the composition of the present invention include maltol, vanillin, ethyl vanillin, menthol, citric acid, fumaric acid, ethyl maltol and tartaric acid.
- Solid and liquid compositions may also be dyed using any pharmaceutically acceptable colorant to improve their appearance and/or facilitate patient identification of the product and unit dosage level.
- In liquid pharmaceutical compositions of the present invention, ziprasidone and any other solid excipients are dissolved or suspended in a liquid carrier such as water, vegetable oil, alcohol, polyethylene glycol, propylene glycol or glycerin.
- Liquid pharmaceutical compositions may contain emulsifying agents to disperse uniformly throughout the composition an active ingredient or other excipient that is not soluble in the liquid carrier. Emulsifying agents that may be useful in liquid compositions of the present invention include, for example, gelatin, egg yolk, casein, cholesterol, acacia, tragacanth, chondrus, pectin, methyl cellulose, carbomer, cetostearyl alcohol and cetyl alcohol.
- Liquid pharmaceutical compositions of the present invention may also contain a viscosity enhancing agent to improve the mouth-feel of the product and/or coat the lining of the gastrointestinal tract. Such agents include acacia, alginic acid bentonite, carbomer, carboxymethylcellulose calcium or sodium, cetostearyl alcohol, methyl cellulose, ethylcellulose, gelatin guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, maltodextrin, polyvinyl alcohol, povidone, propylene carbonate, propylene glycol alginate, sodium alginate, sodium starch glycolate, starch tragacanth and xanthan gum.
- Sweetening agents such as sorbitol, saccharin, sodium saccharin, sucrose, aspartame, fructose, mannitol and invert sugar may be added to improve the taste.
- Preservatives and chelating agents such as alcohol, sodium benzoate, butylated hydroxy toluene, butylated hydroxyanisole and ethylenediamine tetraacetic acid may be added at levels safe for ingestion to improve storage stability.
- According to the present invention, a liquid composition may also contain a buffer such as gluconic acid, lactic acid, citric acid or acetic acid, sodium gluconate, sodium lactate, sodium citrate or sodium acetate. Selection of excipients and the amounts used may be readily determined by the formulation scientist based upon experience and consideration of standard procedures and reference works in the field.
- The solid compositions of the present invention include powders, granulates, aggregates and compacted compositions. The dosages include dosages suitable for oral, buccal, rectal, parenteral (including subcutaneous, intramuscular, and intravenous), inhalant and ophthalmic administration. Although the most suitable administration in any given case will depend on the nature and severity of the condition being treated, the most preferred route of the present invention is oral. The dosages may be conveniently presented in unit dosage form and prepared by any of the methods well-known in the pharmaceutical arts.
- Dosage forms include solid dosage forms like tablets, powders, capsules, suppositories, sachets, troches and losenges, as well as liquid syrups, suspensions and elixirs.
- The dosage form of the present invention may be a capsule containing the composition, preferably a powdered or granulated solid composition of the invention, within either a hard or soft shell. The shell may be made from gelatin and optionally contain a plasticizer such as glycerin and sorbitol, and an opacifying agent or colorant.
- The active ingredient and excipients may be formulated into compositions and dosage forms according to methods known in the art.
- A composition for tableting or capsule filling may be prepared by wet granulation. In wet granulation, some or all of the active ingredients and excipients in powder form are blended and then further mixed in the presence of a liquid, typically water, that causes the powders to clump into granules. The granulate is screened and/or milled, dried and then screened and/or milled to the desired particle size. The granulate may then be tableted, or other excipients may be added prior to tableting, such as a glidant and/or a lubricant.
- A tableting composition may be prepared conventionally by dry blending. For example, the blended composition of the actives and excipients may be compacted into a slug or a sheet and then comminuted into compacted granules. The compacted granules may subsequently be compressed into a tablet.
- As an alternative to dry granulation, a blended composition may be compressed directly into a compacted dosage form using direct compression techniques. Direct compression produces a more uniform tablet without granules. Excipients that are particularly well suited for direct compression tableting include microcrystalline cellulose, spray dried lactose, dicalcium phosphate dihydrate and colloidal silica. The proper use of these and other excipients in direct compression tableting is known to those in the art with experience and skill in particular formulation challenges of direct compression tableting.
- A capsule filling of the present invention may comprise any of the aforementioned blends and granulates that were described with reference to tableting, however, they are not subjected to a final tableting step.
- The solid compositions of the present invention include powders, granulates, aggregates and compacted compositions. The dosages include dosages suitable for oral, buccal, rectal, parenteral (including subcutaneous, intramuscular, and intravenous), inhalant and ophthalmic administration. Although the most suitable route in any given case will depend on the nature and severity of the condition being treated, the most preferred route of the present invention is oral. The dosages can be conveniently presented in unit dosage form and prepared by any of the methods well-known in the pharmaceutical arts.
- The dosage of GEODON may be used as a guidance. The oral dosage form of the present invention is preferably in the form of an oral capsule having a dosage of about 10 mg to about 160 mg, more preferably of about 20 mg to about 80 mg, and most preferably capsules of 20, 40, 60 and 80 mg.
- Instrumentation:
- X-Ray powder diffraction data were obtained using by method known in the art using a SCINTAG powder X-Ray diffractometer model X'TRA equipped with a solid state detector. Copper radiation of 1.5418 Å was used. A round aluminum sample holder with round zero background quartz plate, with cavity of 25(diameter)*0.5(dept) mm.
- DSC analysis was done using a Mettler 821 Stare. The weight of the samples was about 5 mg; the samples were scanned at a rate of 10° C./min from 30° C. to 320° C. The oven was constantly purged with nitrogen gas at a flow rate of 40 ml/min.
Standard 40 μl aluminum crucibles covered by lids with 3 holes were used. - TGA analysis was done using a Mettler M3 meter. The weight of the samples was about 10 mg; the samples were scanned at a rate of 10° C./min from 25° C. to 200° C. The oven was constantly purged with nitrogen gas at a flow rate of 40 ml/min. Standard 70 μl alumina crucibles covered by lids with 1 hole were used.
- IR analysis was done using a Perkin Elmer SPECTRUM ONE FT-IR spectrometer in DRIFTt mode. The samples in the 4000400 cm−1 interval were scanned 16 times with 4.0 cm−1 resolution.
- The water content of ziprasidone HCl was measured by the methods known in the art like Karl Fisher or thermogravimetric analysis (TGA). In the case of ziprasidone HCl F, the TGA and Karl Fisher analysis matched, while for ziprasidone HCl form E the TGA analysis exceeded by far that of Karl Fisher, as an indication that a significant quantity of solvent is present.
- Ziprasidone Base
- Ziprasidone free base used for preparations of the crystal forms of ziprasidone HCl is characterized by X-Ray peaks at 12.1, 15.2, 16.3, 18.4, 25.0
degrees 2 theta and is further characterized by XRD peaks at 5.2, 10.4, 11.3, 13.1, 21.1, 22.1. The ziprasidone free base has a DSC thermogram like the one shown inFIG. 13 , in which 17 and 120 J/g endothermic peaks can be seen at 92 and 220° C. The first corresponds to dehydration, the second to melting of the ziprasidone free base. The water content of the sample of the base is about 1.2% by weight. The Loss on Drying by TGA is about 2.1% by weight. The IR spectrum of ziprasidone free base is substantially depicted inFIG. 14 . The form of ziprasidone is referred to as Form B. One of skill in the art would appreciate that the processes of the present invention may use other forms of ziprasidone base as starting material. - Ziprasidone base for the experiments below was prepared according to the procedure “EXPERIMENT” in U.S. Pat. No. 5,312,925,
column 4. The water content of the base was 1.2% (Karl Fisher). - Ziprasidone base (50 g) and toluene (250 ml) were charged into a 0.5 L three necked flask. The obtained slurry was heated at 85° C. for 2 hours. The hot slurry was filtrated and the solid was washed with methanol. The solid was dried in air-circulated oven at 50° C. to afford the dried Ziprasidone base form B (by XRD) (45.39 g).
- Aqueous HCl (37%) (10 ml) was added to a slurry of ziprasidone base Form B (10 g) in acetonitrile (200 ml) at reflux. After the addition, the slurry was heated over night. A solid was filtered and washed with acetonitrile. After drying at 50° C. for ˜16 hours, ziprasidone HCl Form E was obtained (12.71 g) (The water content was 9.25% by K.F. and the loss on drying by TGA is 18.8%), as confirmed by XRD.
- A slurry of ziprasidone base form B (10 g) in ethyl acetate (100 ml) was heated at reflux without complete dissolution. The slurry was then cooled. When the temperature was about 50° C., aqueous HCl (37%) (10 ml) was added, and the slurry was diluted by addition of ethyl acetate (100 ml). The slurry was stirred for ˜16 hours. A solid was filtered and washed with ethyl acetate. The wet solid was ziprasidone HCl Form E, as confirmed by XRD. The wet solid was dried at 50° C. The dried solid had a water content of 9.62% (by K.F.) and a loss on drying of 19% (by TGA). The dried solid was Form E, as confirmed by XRD.
- Aqueous HCl (37%) (10 ml) was added drop-wise to a hot slurry of ziprasidone base Form B (10 g) in methylethylketone (MEK) (200 ml). The slurry was stirred at room temperature over night. A solid was filtered and washed with MEK. The wet solid was ziprasidone HCl Form F. The wet solid was dried at 50° C. for two days. The dried product was ziprasidone HCl Form F (10.62 g) (The water content was 3.87% by K.F. and the loss on drying is 4.1% by TGA), as confirmed by XRD.
- Aqueous hydrochloric acid (37%) (910 ml) was added to a hot slurry of ziprasidone base (10 g) in tetrahydrofuran (THF) (200 ml). The slurry was stirred at room temperature for about 16 hours. A solid was filtered, washed with THF and dried in an oven at 50° C. for two days. The wet and the dried solid samples were ziprasidone HCl Form F (The water content was 3.63%), as confirmed by XRD.
- Ziprasidone base (10 g) was dissolved in dimethylacetamide (100 ml) at ˜95° C. The solution was cooled to 70° C. and aqueous HCl (37%) (10 ml) was added, resulting in precipitation and formation of a slurry. The slurry was then cooled to room temperature, followed by addition of water (100 ml). Stirring was continued for 1 hour at room temperature, followed by filtration, and washing of a solid material obtained from filtration with water. The wet solid was dried at 50° C. for about 16 hours to a dry solid (7.1 g). The wet and the dried solid were ziprasidone HCl Form F in mixture with Form M (The water content of the dried solid is 4.17% by K.F.), as confirmed by XRD.
- Ziprasidone hydrochloride Form E (4.05 g) was heated at 80-105° C. in an oven for about 16 hours. The solid after heating was ziprasidone HCl amorphous (3.33 g) (The water content was 1.21% by K.F.), as confirmed by XRD.
- Ziprasidone base (10 g) was taken in dimethylcarbonate (DMC) (100 ml) and the mixture was heated at ˜90° C. Aqueous HCl (37%) (10 ml) was added, resulting in a sticky material. Additional amount of DMC (100 ml), and methanol (50 ml), were added, resulting in a slurry. The slurry was stirred at room temperature over night. A solid was filtered and washed with DMC, and subsequently dried at 50° C. overnight. The wet and the dried solids were ziprasidone HCl monohydrate, as confirmed by XRD. The water content of the dried solid by K.F. is 4.78%.
- In all the above examples except example 8, drying was carried out in an air-circulated oven. In example 8, the pressure was atmospheric pressure.
- Ziprasidone base Form B (10 g) was added to ethyl-lactate (50 ml) and the slurry obtained was cooled to 5° C. HCl(g) was bubbled through the above slurry and ether (150 ml) was added. The slurry was stirred over night at room temperature, filtrated and washed with ether. The wet material was dried at 50° C. in an air-circulated oven and ziprasidone HCl Form G was obtained.
- Ziprasidone base Form B (5 g) was added to carbon-tetrachloride (50 ml) and HCl(g) was bubbled until
pH 1 was reached. The temperature rose to ˜40° C. The slurry was stirred at room temperature for 3 hours and filtrated. The solid was dried in an air-circulated oven at 50° C. for 17 hours. The wet and the dried solid both were ziprasidone HCl Form G. - Ziprasidone base Form B (10 g) was added to di-iso-propyl-ether (200 ml) and the slurry was stirred at room temperature; through the slurry HCl(g) was bubbled while the temperature rose to ˜50° C. The slurry was stirred at room temperature over-night, the solid was filtrated and washed with di-iso-propyl-ether. The wet solid gave ziprasidone HCl Form G. Drying of the wet solid in an air-circulated oven at 50° C. for ˜16 h gave ziprasidone HCl Form I.
- Ziprasidone base Form B (10 g) was added to ethyl-acetate (200 ml) and HCl(g) was bubbled through the slurry; the temperature rose to ˜35° C. The slurry was stirred at room temperature for 3 hours and the solid was filtrated, washed with ethyl-acetate and dried for ˜16 h in an air-circulated oven at 45° C. The wet and dried solids both gave a mixture of ziprasidone HCl Form G and F.
- Concentrated HCl (37%) was added to the slurry of ziprasidone base (form B) (10 g) in ethyl-lactate (200 ml) at 60° C. The reaction mixture was stirred at room temperature for about 16 hours, and a solid was filtrated, washed with ethyl-lactate (20 ml) and dried at 50° C. for two days. The solid was ziprasidone HCl Form M. (K.F. 4.02%).
- To the slurry of ziprasidone base (Form B) (10 g) in ethanol (200 ml) at room temperature was added concentrated hydrochloric acid 37% (˜5 g); the temperature rose to ˜30° C. during the HCl addition. The slurry was than stirred at room temperature for about 16 hours. A solid was filtrated, washed with ethanol and dried in an air-circulated oven at 50° C. The product was ziprasidone HCl form M. (K.F. 4.37%).
- To the slurry of ziprasidone base (Form B) (10 g) in methanol (100 ml) at 5° C. was bubbled HCl(g); the obtained slurry was then stirred over night at room temperature. A solid was filtrated, washed with methanol and dried at 50° C. for about 16 hours. The product was ziprasidone HCl Form M (KF. 4.5%).
- To the slurry of ziprasidone base (Form B) (10 g) in methanol (200 ml) at 60° C. was added concentrated HCl (10 ml); the slurry was then stirred at room temperature for about 16 hours. A solid was filtrated, washed with methanol (2×10 ml) and dried at 50° C. in an air-circulated oven for 2 days. The product was ziprasidone HCl Form M (K.F. 4.26%).
- A slurry of ziprasidone base (Form B) (10 g) in n-butanol (250 ml) was heated to 60° C. While maintaining the temperature, concentrated HCl was added (10 ml). The reaction mixture was than stirred at room temperature for about 16 hours. A solid was filtrated, washed with n-butanol (2×20 ml) and dried for about 16 hours at 50° C. in an air-circulated oven. The dried solid was ziprasidone HCl Form M (K.F. 4.12%).
- To the slurry of ziprasidone base. (Form B) (10 g) in acetone (200 ml) at room temperature was added concentrated HCl (100 ml); the temperature rose to about 30° C. The reaction mixture was stirred at room temperature for about 16 hours. A solid was filtrated, washed with acetone (2×10 ml) and dried for two days in an air-circulated oven at 50° C. The dried solid was ziprasidone HCl Form M (K.F. 4.57%).
- A slurry of ziprasidone HCl Form F (5 g) in THF/water 95:5 (50 ml) was heated at 50° C. for two hours. After cooling to room temperature, a solid was filtrated, washed with mixture THF/water and dried for 18 hours in an air-circulated oven. The dried solid was ziprasidone HCl Form M (K.F. 4.50%).
- Ziprasidone HCl Form E (2 g) was heated in n-butanol (200 ml) and water (40 ml) at 85° C.; complete dissolution was not obtained. More water was added (20 ml) and the slurry was stirred at 90° C. for 1.5 hours. A solid was filtrated from the hot slurry, washed with n-butanol/water (4 ml 3:1) and dried. From the filtrate a solid was obtained upon cooling to 10° C. This material was filtrated, washed and dried in the same conditions. Both dried solids were ziprasidone HCl Form M.
- Aqueous HCl was drop-wise added over 10 minutes, to a slurry of ziprasidone base (5 g) in toluene (100 ml) at room temperature. The obtained mixture was stirred at room temperature for 3 hours, and then the solvent was evaporated under vacuum. The solid obtained after the toluene evaporation was ziprasidone HCl Form J.
- The above material (ZPR HCl form J form Example 20) was dried by maintaining it at 40° C. and under nitrogen atmosphere over night, followed by additional drying with a rotary evaporator. The dried material collected after the two drying stages was ziprasidone HCl Form E1 (water content by K.F. ˜6% and ˜8% respectively).
- In a 250 ml three necked flask were charged Ziprasidone base (5 g) and a mixture 9:1 THF:acetic acid. The slurry was heated at 60° C. and more solvent was added until complete dissolution was obtained. The total volume of the solvents mixture was 175 ml. To the
solution 4 drops of 10% hydrochloric acid was added; upon HCl addition a precipitate is formed. The hazy solution was stirred for 1 h at 60° C. and after this 15ml 10% HCl was added over 30 minutes. The slurry was than stirred for 2.5 h maintaining the temperature at 60° C. The solid was filtrated from the slurry after cooling to room temperature and washed with solvent. The solid obtained after drying at 50° C. is ZPR HCl Form M substantially pure of form A. (4.58 g). (Water content by K.F. 4.04%). - In a 250 ml three necked flask were charged Ziprasidone base (5 g) and mixture of THF:MeOH 10:3. The mixture was heated at 60° C. and diluted with the solvents until the complete dissolution was observed. (the total volume is 240 ml.).
Hydrochloric acid 10% (2 ml) was added and the reaction mixture was stirred for 30 minutes. After this period of time more hydrochloric acid was added to complete the reaction. The stirring was continued for 1 h at 60° C.; the mixture was than cooled to room temperature and the solid filtrated and washed with solvent. After drying at 50° C. the ZPR HCl Form M substantially pure of form A was obtained. (Water content by K.F. 4.08%). - In a 250 ml three necked flask were charged Ziprasidone base (5 g) and n-BuOH (100 ml) and the slurry was heated at 60° C. Acetic acid was added (10 ml) and more n-BuOH (100 ml). To the
slurry 10% hydrochloric acid (2 ml) was added and the mixture was stirred for 1 h. After this more HCl was added drop-wise over 30′. The reaction mixture was stirred for 1 h at 60° C. to complete the reaction. After cooling to the room temperature the solid was filtrated, washed with solvent and dried at 50° C. to give ZPR HCl Form M substantially pure of form A (4.25 g). (Water content by K.F. 4.33%). - In a 250 ml three necked flask were charged Ziprasidone base (5 g) and N,N-dimethyl-acetamide (DMA) (100 ml) and the mixture has been heated at 60° C. To the obtained solution 32% HCl (3 ml) was added and the stirring was continued for 4 h. After cooling, the solid was filtrated and then dried to afford ziprasidone HCl Form M substantially pure of form A.
- (Water content by K.F. 4.15%).
- To the slurry of ziprasidone base (5 g) in toluene (100 ml) at room temperature was drop-wise added aqueous HCl over 10 minutes. The obtained mixture was stirred at room temperature for 3 hours, then the solvent was distilled under vacuum. The solid obtained after the toluene distillation was ziprasidone HCl Form J.
- The above material (ZPR HCl form J) was dried by maintaining it at 40° C. and under nitrogen over night, followed by an additional drying operation on a rotary evaporator. The dried material collected in the two drying stages was ziprasidone HCl Form E1 (water content by K.F. 6% and 7.8% respectively).
- To the chilled slurry of ZPR base (5 g) in methylethyl-ketone (MEK) (100 ml) (˜2° C.) Was bubbled hydrogen chloride until the
pH 1 was reached. The temperature was in therange 2 to 10° C. The slurry was than stirred at the above temperature for 5 hours, the solid was filtrated and washed with MEK (2×10 ml). After drying at 60° C. was obtained a solid which is ZPR.HCl amorphous by XRD. - Having thus described the invention with reference to particular preferred embodiments and illustrative examples, those in the art can appreciate modifications to the invention as described and illustrated that do not depart from the spirit and scope of the invention as disclosed in the specification. The Examples are set forth to aid in understanding the invention but are not intended to, and should not be construed to, limit its scope in any way. The examples do not include detailed descriptions of conventional methods. Such methods are well known to those of ordinary skill in the art and are described in numerous publications. Polymorphism in Pharmaceutical Solids, Drugs and the Pharmaceutical Sciences, Volume 95 may be used for guidance. All references mentioned herein are incorporated in their entirety.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/999,337 US20080090835A1 (en) | 2003-06-03 | 2007-12-03 | Polymorphic forms of ziprasidone HCl and processes for their preparation |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47580603P | 2003-06-03 | 2003-06-03 | |
US48791303P | 2003-07-16 | 2003-07-16 | |
US49497003P | 2003-08-13 | 2003-08-13 | |
US52834603P | 2003-12-09 | 2003-12-09 | |
US57199704P | 2004-05-17 | 2004-05-17 | |
US10/860,926 US20050043324A1 (en) | 2003-06-03 | 2004-06-03 | Polymorphic forms of ziprasidone HCI and processes for their preparation |
US11/999,337 US20080090835A1 (en) | 2003-06-03 | 2007-12-03 | Polymorphic forms of ziprasidone HCl and processes for their preparation |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/860,926 Division US20050043324A1 (en) | 2003-06-03 | 2004-06-03 | Polymorphic forms of ziprasidone HCI and processes for their preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080090835A1 true US20080090835A1 (en) | 2008-04-17 |
Family
ID=34199327
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/860,864 Expired - Fee Related US7678799B2 (en) | 2003-06-03 | 2004-06-03 | Crystalline ziprasidone HCl and processes for preparation thereof |
US10/860,926 Abandoned US20050043324A1 (en) | 2003-06-03 | 2004-06-03 | Polymorphic forms of ziprasidone HCI and processes for their preparation |
US11/804,301 Abandoned US20070238738A1 (en) | 2003-06-03 | 2007-05-16 | Crystalline ziprasidone HCI and processes for preparation thereof |
US11/999,337 Abandoned US20080090835A1 (en) | 2003-06-03 | 2007-12-03 | Polymorphic forms of ziprasidone HCl and processes for their preparation |
US11/999,453 Abandoned US20080091020A1 (en) | 2003-06-03 | 2007-12-03 | Polymorphic forms of ziprasidone HCI and processes for their preparation |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/860,864 Expired - Fee Related US7678799B2 (en) | 2003-06-03 | 2004-06-03 | Crystalline ziprasidone HCl and processes for preparation thereof |
US10/860,926 Abandoned US20050043324A1 (en) | 2003-06-03 | 2004-06-03 | Polymorphic forms of ziprasidone HCI and processes for their preparation |
US11/804,301 Abandoned US20070238738A1 (en) | 2003-06-03 | 2007-05-16 | Crystalline ziprasidone HCI and processes for preparation thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/999,453 Abandoned US20080091020A1 (en) | 2003-06-03 | 2007-12-03 | Polymorphic forms of ziprasidone HCI and processes for their preparation |
Country Status (6)
Country | Link |
---|---|
US (5) | US7678799B2 (en) |
EP (2) | EP1546146A1 (en) |
KR (4) | KR100880279B1 (en) |
CA (2) | CA2528192A1 (en) |
IL (2) | IL172005A0 (en) |
WO (2) | WO2005016325A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013071272A1 (en) * | 2011-11-11 | 2013-05-16 | Intellikine, Llc | Kinase inhibitor polymorphs |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE450529T1 (en) | 2001-02-27 | 2009-12-15 | Governement Of The United Stat | ANALOGUE OF THALIDOMIDE AS ANGIOGENESIS INHIBITORS |
US20080312254A1 (en) | 2004-02-27 | 2008-12-18 | Ranbaxy Laboratories Limited | Process for the Preparation of Ziprasidone |
WO2005100348A1 (en) * | 2004-04-15 | 2005-10-27 | Lupin Limited | Amorphous ziprasidone hydrochloride |
ITMI20040944A1 (en) * | 2004-05-11 | 2004-08-11 | Dinamite Dipharma S P A In For | ZIPRASIDONE HYDROCHLORIDE POLYMORPH AND PROCEDURE FOR ITS PREPARATION |
CA2467538C (en) | 2004-05-14 | 2010-08-24 | Apotex Pharmachem Inc. | New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same |
ES2250001B1 (en) * | 2004-09-29 | 2007-06-01 | Medichem, S.A. | PROCESS FOR THE PURIFICATION OF ZIPRASIDONA. |
ITMI20050346A1 (en) * | 2005-03-07 | 2006-09-08 | Dipharma Spa | SOLID FORM OF CHLORIDATED ZIPRASIDONE |
CA2500667C (en) * | 2005-03-11 | 2013-01-15 | Apotex Pharmachem Inc. | Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions |
KR100989389B1 (en) * | 2010-06-15 | 2010-10-25 | 화일약품주식회사 | Novel crystalline ziprasidone hcl and processes for preparation thereof |
SI23610A (en) | 2011-01-13 | 2012-07-31 | Diagen@d@o@o | New addition salts of ziprasidone, process for their preparation and their use in therapy |
AR099354A1 (en) | 2013-11-15 | 2016-07-20 | Akebia Therapeutics Inc | SOLID FORMS OF ACID {[5- (3-CHLOROPHENYL) -3-HYDROXIPIRIDIN-2-CARBON] AMINO} ACETIC, COMPOSITIONS, AND ITS USES |
WO2023108156A1 (en) * | 2021-12-11 | 2023-06-15 | Beloteca, Inc. | Ziprasidone formulations |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
US5206366A (en) * | 1992-08-26 | 1993-04-27 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds |
US5312925A (en) * | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
US5338846A (en) * | 1992-08-26 | 1994-08-16 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt |
US5359068A (en) * | 1993-06-28 | 1994-10-25 | Pfizer Inc. | Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one |
US6110918A (en) * | 1996-05-07 | 2000-08-29 | Pfizer Inc | Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist |
US6150366A (en) * | 1998-06-15 | 2000-11-21 | Pfizer Inc. | Ziprasidone formulations |
US20020016498A1 (en) * | 2000-05-26 | 2002-02-07 | Am Ende David J. | Reactive crystallization method to improve particle size |
US20040048876A1 (en) * | 2002-02-20 | 2004-03-11 | Pfizer Inc. | Ziprasidone composition and synthetic controls |
US20050143396A1 (en) * | 2003-04-11 | 2005-06-30 | Hertero Drugs Limited | Novel crystalline forms of ziprasidone hydrochloride |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0680874A (en) | 1992-08-31 | 1994-03-22 | Nippon G Ii Plast Kk | Thermoplastic polyester elastomer resin composition |
UA57734C2 (en) * | 1996-05-07 | 2003-07-15 | Пфайзер Інк. | Arylheterocyclic inclusion complexes |
TW491847B (en) * | 1996-05-07 | 2002-06-21 | Pfizer | Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one |
BR0307333A (en) * | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Methods for preparing homogeneous dispersions of atomized amorphous solid drugs using a spray drying system |
UY27668A1 (en) | 2002-02-20 | 2003-10-31 | Pfizer Prod Inc | ZIPRASIDONE COMPOSITION AND SYNTHETIC CONTROLS |
WO2004050655A1 (en) | 2002-12-04 | 2004-06-17 | Dr. Reddy's Laboratories Limited | Polymorphic forms of ziprasidone and its hydrochloride |
CN1255105C (en) | 2002-12-17 | 2006-05-10 | 上海医药工业研究院 | Water soluble dressing materials of ziracitone and its salts and their preparation |
AU2003297836A1 (en) | 2003-01-29 | 2004-08-30 | Fisher Controls International Llc | Valve travel indicator |
-
2004
- 2004-06-03 EP EP04754586A patent/EP1546146A1/en not_active Withdrawn
- 2004-06-03 KR KR1020057023242A patent/KR100880279B1/en not_active IP Right Cessation
- 2004-06-03 WO PCT/US2004/018017 patent/WO2005016325A2/en active Application Filing
- 2004-06-03 KR KR1020087023696A patent/KR20080093164A/en not_active Application Discontinuation
- 2004-06-03 WO PCT/US2004/018018 patent/WO2005035531A1/en active Application Filing
- 2004-06-03 US US10/860,864 patent/US7678799B2/en not_active Expired - Fee Related
- 2004-06-03 CA CA002528192A patent/CA2528192A1/en not_active Abandoned
- 2004-06-03 KR KR1020057023243A patent/KR20060015750A/en not_active Application Discontinuation
- 2004-06-03 EP EP04754585A patent/EP1530570A2/en not_active Withdrawn
- 2004-06-03 CA CA002528100A patent/CA2528100A1/en not_active Abandoned
- 2004-06-03 KR KR1020087003877A patent/KR20080022595A/en not_active Application Discontinuation
- 2004-06-03 US US10/860,926 patent/US20050043324A1/en not_active Abandoned
-
2005
- 2005-11-16 IL IL172005A patent/IL172005A0/en unknown
- 2005-11-16 IL IL172004A patent/IL172004A0/en unknown
-
2007
- 2007-05-16 US US11/804,301 patent/US20070238738A1/en not_active Abandoned
- 2007-12-03 US US11/999,337 patent/US20080090835A1/en not_active Abandoned
- 2007-12-03 US US11/999,453 patent/US20080091020A1/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
US5206366A (en) * | 1992-08-26 | 1993-04-27 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds |
US5338846A (en) * | 1992-08-26 | 1994-08-16 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt |
US5312925A (en) * | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
US5359068A (en) * | 1993-06-28 | 1994-10-25 | Pfizer Inc. | Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one |
US6110918A (en) * | 1996-05-07 | 2000-08-29 | Pfizer Inc | Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist |
US6150366A (en) * | 1998-06-15 | 2000-11-21 | Pfizer Inc. | Ziprasidone formulations |
US20020016498A1 (en) * | 2000-05-26 | 2002-02-07 | Am Ende David J. | Reactive crystallization method to improve particle size |
US20040048876A1 (en) * | 2002-02-20 | 2004-03-11 | Pfizer Inc. | Ziprasidone composition and synthetic controls |
US20050143396A1 (en) * | 2003-04-11 | 2005-06-30 | Hertero Drugs Limited | Novel crystalline forms of ziprasidone hydrochloride |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013071272A1 (en) * | 2011-11-11 | 2013-05-16 | Intellikine, Llc | Kinase inhibitor polymorphs |
JP2014533285A (en) * | 2011-11-11 | 2014-12-11 | インテリカイン, エルエルシー | Kinase inhibitor polymorphs |
US9403820B2 (en) | 2011-11-11 | 2016-08-02 | Intellikine Llc | Kinase inhibitor polymorphs |
Also Published As
Publication number | Publication date |
---|---|
WO2005016325A3 (en) | 2005-03-24 |
KR20060015750A (en) | 2006-02-20 |
IL172004A0 (en) | 2009-02-11 |
US20050059680A1 (en) | 2005-03-17 |
EP1530570A2 (en) | 2005-05-18 |
US7678799B2 (en) | 2010-03-16 |
EP1546146A1 (en) | 2005-06-29 |
CA2528100A1 (en) | 2005-04-21 |
KR20080093164A (en) | 2008-10-20 |
IL172005A0 (en) | 2009-02-11 |
US20050043324A1 (en) | 2005-02-24 |
WO2005016325A2 (en) | 2005-02-24 |
KR20060024788A (en) | 2006-03-17 |
WO2005035531A1 (en) | 2005-04-21 |
US20070238738A1 (en) | 2007-10-11 |
KR100880279B1 (en) | 2009-01-28 |
CA2528192A1 (en) | 2005-02-24 |
KR20080022595A (en) | 2008-03-11 |
US20080091020A1 (en) | 2008-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080090835A1 (en) | Polymorphic forms of ziprasidone HCl and processes for their preparation | |
US7439373B2 (en) | Crystalline mycophenolate sodium | |
US20080091017A1 (en) | Polymorphic form B2 of ziprasidone base | |
US20210387952A1 (en) | Solid state forms of daprodustat and process for preparation thereof | |
US7417165B2 (en) | Crystalline forms of pregabalin | |
US20230057197A1 (en) | Solid state forms of mavacamten and process for preparation thereof | |
US20230339962A1 (en) | Solid state forms of sep-363856 and process for preparation thereof | |
US20040229896A1 (en) | Stable pharmaceutical compositions of desloratadine | |
US20040235904A1 (en) | Crystalline and amorphous solids of pantoprazole and processes for their preparation | |
US20220135548A1 (en) | Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1h)-isoquinolinyl)ethyl]phenyl}-2h-tetrazol-5-yl)-4,5- dimethoxyphenyl]-4-oxo-4h-chromene-2-carboxamide and of its mesylate salt | |
US20230167090A1 (en) | Solid state forms of aprocitentan and process for preparation thereof | |
US20230098234A1 (en) | Solid state forms of mitapivat and process for preparation thereof | |
US20220356165A1 (en) | Solid state forms of roluperidone and salts thereof | |
US20230058102A1 (en) | Solid state forms of blarcamesine salts | |
US20220153744A1 (en) | Solid state forms of acalabrutinib | |
US20060270684A1 (en) | Crystalline forms of ziprasidone mesylate | |
US20220380288A1 (en) | Solid state forms of fezagepras and process for preparation thereof | |
US20070066594A1 (en) | Crystalline forms fenoldopam mesylate | |
US20230357163A1 (en) | Solid state forms of gefapixant and process for preparation thereof | |
US20240173304A1 (en) | Solid state forms of tideglusib and process for preparation thereof | |
US20230071463A1 (en) | Solid state forms of avasopasem manganese and process for preparation thereof | |
US20240051964A1 (en) | Solid state forms of capivasertib and process for preparation thereof | |
US20210395193A1 (en) | New crystalline polymorphs of rigosertib sodium | |
WO2023199258A1 (en) | Solid state forms of mavacamten and process for preparation thereof | |
WO2023164024A1 (en) | Solid state forms of gusacitinib |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TEVA PHARMACEUTICAL INDUSTRIES LTD., ISRAEL Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOLTAI, TAMAS;HEDVATI, LILACH;MENDELOVICI, MARIOARA;AND OTHERS;REEL/FRAME:020247/0738;SIGNING DATES FROM 20040922 TO 20040928 Owner name: TEVA PHARMACEUTICALS USA, INC., PENNSYLVANIA Free format text: ASSIGNMENT OF RIGHTS IN BARBADOS;ASSIGNOR:TEVA PHARMACEUTICAL INDUSTRIES LTD.;REEL/FRAME:020249/0909 Effective date: 20070829 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |